<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">63677</article-id><article-id pub-id-type="doi">10.7554/eLife.63677</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Stem cell transplantation rescued a primary open-angle glaucoma mouse model</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-174015"><name><surname>Xiong</surname><given-names>Siqi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174016"><name><surname>Kumar</surname><given-names>Ajay</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3412-1823</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174017"><name><surname>Tian</surname><given-names>Shenghe</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174018"><name><surname>Taher</surname><given-names>Eman E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174019"><name><surname>Yang</surname><given-names>Enzhi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174020"><name><surname>Kinchington</surname><given-names>Paul R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1901-9970</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174021"><name><surname>Xia</surname><given-names>Xiaobo</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-156058"><name><surname>Du</surname><given-names>Yiqin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4330-0957</contrib-id><email>duy@upmc.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Department of Ophthalmology, University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Eye Center of Xiangya Hospital, Central South University</institution><addr-line><named-content content-type="city">Changsha</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>Hunan Key Laboratory of Ophthalmology</institution><addr-line><named-content content-type="city">Changsha</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution>Research Institute of Ophthalmology</institution><addr-line><named-content content-type="city">Giza</named-content></addr-line><country>Egypt</country></aff><aff id="aff5"><label>5</label><institution>Department of Developmental Biology, University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>McGowan Institute for Regenerative Medicine, University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Pera</surname><given-names>Martin</given-names></name><role>Reviewing Editor</role><aff><institution>The Jackson Laboratory</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Bronner</surname><given-names>Marianne E</given-names></name><role>Senior Editor</role><aff><institution>California Institute of Technology</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>28</day><month>01</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e63677</elocation-id><history><date date-type="received" iso-8601-date="2020-10-02"><day>02</day><month>10</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-01-22"><day>22</day><month>01</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Xiong et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Xiong et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-63677-v2.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="article-reference" xlink:href="10.7554/eLife.54900"/><abstract><p>Glaucoma is a leading cause of irreversible blindness. In this study, we investigated if transplanted stem cells are able to rescue a glaucoma mouse model with transgenic myocilin Y437H mutation and explored the possible mechanisms. Human trabecular meshwork stem cells (TMSCs) were intracamerally transplanted which reduced mouse intraocular pressure, increased outflow facility, protected the retinal ganglion cells and preserved their function. TMSC transplantation also significantly increased the TM cellularity, promoted myocilin secretion from TM cells into the aqueous humor to reduce endoplasmic reticulum stress, repaired the TM tissue with extracellular matrix modulation and ultrastructural restoration. Co-culturing TMSCs with myocilin mutant TM cells in vitro promoted TMSCs differentiating into phagocytic functional TM cells. RNA sequencing revealed that TMSCs had upregulated genes related to TM regeneration and neuroprotection. Our results uncovered therapeutic potential of TMSCs for curing glaucoma and elucidated possible mechanisms by which TMSCs achieve the treatment effect.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>stem cells</kwd><kwd>trabecular meshwork</kwd><kwd>transplantation</kwd><kwd>glaucoma</kwd><kwd>mouse model</kwd><kwd>RNAseq</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>EY025643</award-id><principal-award-recipient><name><surname>Du</surname><given-names>Yiqin</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>P30-EY008098</award-id><principal-award-recipient><name><surname>Du</surname><given-names>Yiqin</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001818</institution-id><institution>Research to Prevent Blindness</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Du</surname><given-names>Yiqin</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001607</institution-id><institution>Eye and Ear Foundation of Pittsburgh</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Du</surname><given-names>Yiqin</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Stem cell transplantation reduces intraocular pressure and preserves retinal ganglion cell function in a mouse glaucoma model, which could lead to a novel therapy for glaucoma to preserve vision.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Primary open-angle glaucoma (POAG), the most common type of glaucoma with a prevalence of 0.5–7.0% in adults, can result in damage of retinal ganglion cells (RGCs) and irreversible vision loss (<xref ref-type="bibr" rid="bib7">Broman et al., 2008</xref>; <xref ref-type="bibr" rid="bib36">Quigley, 2006</xref>). The progression of POAG has been demonstrated to be correlated with elevated intraocular pressure (IOP) (<xref ref-type="bibr" rid="bib19">Heijl et al., 2002</xref>), which is associated with reduced trabecular meshwork (TM) cellularity (<xref ref-type="bibr" rid="bib4">Alvarado et al., 1984</xref>; <xref ref-type="bibr" rid="bib3">Alvarado et al., 1981</xref>), malfunction of TM phagocytosis (<xref ref-type="bibr" rid="bib8">Buller et al., 1990</xref>) and abnormal deposition of extracellular matrix (ECM) (<xref ref-type="bibr" rid="bib18">Gong, 2016</xref>; <xref ref-type="bibr" rid="bib23">Keller et al., 2009</xref>). Replenishment of the TM cells with stem cells and restoration of the TM function offers a novel alternative approach to treat POAG (<xref ref-type="bibr" rid="bib1">Abu-Hassan et al., 2015</xref>; <xref ref-type="bibr" rid="bib13">Du et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Du et al., 2013</xref>; <xref ref-type="bibr" rid="bib25">Kelley et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Zhou et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Zhu et al., 2016</xref>).</p><p>Trabecular meshwork stem cells (TMSCs) have their special niche located at the anterior TM tissue beneath the Schwalbe’s line (<xref ref-type="bibr" rid="bib6">Braunger et al., 2014</xref>; <xref ref-type="bibr" rid="bib37">Raviola, 1982</xref>; <xref ref-type="bibr" rid="bib42">Sundaresan et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Yun et al., 2016</xref>) and have been successfully isolated and characterized (<xref ref-type="bibr" rid="bib10">Castro and Du, 2019</xref>; <xref ref-type="bibr" rid="bib13">Du et al., 2012</xref>). TMSCs maintain stem cell characteristics and regenerative capacity after long-term cryopreservation (<xref ref-type="bibr" rid="bib27">Kumar et al., 2020</xref>), which can be an effective source for cell-based therapy. After intracameral injection, TMSCs exhibit the preference to home to the TM region in wild-type mice (<xref ref-type="bibr" rid="bib14">Du et al., 2013</xref>) and to laser-damaged TM tissue, which is correlated with CXCR4/SDF1 chemokine axis (<xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>). Moreover, TMSCs can improve the outflow facility in a mouse model with laser-induced TM damage (<xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>). However, the mechanisms for TMSCs repairing the diseased TM and restoring TM function in POAG have not yet been resolved. Intriguingly, the pathogenesis of POAG is apparently different from that of laser-induced glaucoma (<xref ref-type="bibr" rid="bib29">Liesenborghs et al., 2020</xref>). Hence, exploring the therapeutic effect of TMSCs on models of POAG and uncovering mechanisms underlying it are crucial steps for future clinical therapies for treating glaucoma.</p><p>Several factors, such as environment and genetics, have been found to contribute to the occurrence and development of POAG (<xref ref-type="bibr" rid="bib20">Janssen et al., 2013</xref>). Mutations in the gene encoding myocilin (Myoc) have been confirmed to be associated with glaucoma (<xref ref-type="bibr" rid="bib44">Tamm, 2002</xref>) which are responsible for 4% of adult-onset POAG and 10% of juvenile-onset POAG. Although Myoc mutation glaucoma is a subtype of POAG, the pathophysiology of POAG in common is associated with reduced TM cellularity, abnormal deposition of ECM and increased IOP. Myoc mutations alter the structure of Myoc protein and result in the retention of misfolded Myoc in the endoplasmic reticulum (ER) of TM cells. The accumulated protein can then induce ER stress in TM cells, which is related to glaucoma (<xref ref-type="bibr" rid="bib35">Peters et al., 2015</xref>). ER stress can also lead to TM dysfunction, abnormal synthesis and turnover of ECM and loss of RGCs (<xref ref-type="bibr" rid="bib16">Fingert et al., 2002</xref>). A mouse POAG model with transgenic-Myoc Y437H mutation (Tg-MyocY437H) closely mimics the pathophysiology of human Myoc-associated glaucoma (<xref ref-type="bibr" rid="bib55">Zhou et al., 2008</xref>; <xref ref-type="bibr" rid="bib59">Zode et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Zode et al., 2011</xref>). Here, we report that human TMSCs that are intracamerally transplanted to the Tg-MyocY437H POAG mice, can repopulate the TM cells, repair the abnormal TM tissue and preserve the function of RGCs. By analyzing the RNA sequencing (RNAseq) data from three strains of human TMSCs and corneal fibroblasts from different donors, we have identified the expression differences for unveiling the TMSC regeneration mechanisms.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>TMSCs reduce IOP and increase outflow facility of the Tg-MyocY437H mice</title><p>Human TMSCs were isolated as previously described (<xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>) and characterized by flow cytometry to confirm the positive expression of stem cell markers CD73, CD90, CD105, CD166, and negative expression of CD34 and CD45 as previously reported (<xref ref-type="bibr" rid="bib27">Kumar et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>). To investigate therapeutic effect of TMSCs on POAG, human TMSCs at passage three or four were injected into the anterior chamber of the Tg-MyocY437H mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) when they were at age of 4 months. Age-matched wild-type (WT) mice served as control. The baseline IOP of 4-month-old Tg-MyocY437H mice was 16.5 ± 0.44 mmHg (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), which was significantly higher than that of WT mice (12.38 ± 0.41 mmHg, p&lt;0.0001). Tg-MyocY437H mice transplanted with TMSCs started to lower IOP from 1 month after stem cell transplantation, and IOP decreased to 13.30 ± 0.42 mmHg (Tg-TMSC) at 1 month. This was close to that in WT mice (WT, 12.30 ± 0.45 mmHg, p=0.4576). The IOP was significantly lower than IOP of Tg-MyocY437H mice without treatment (Tg, 15.23 ± 0.64 mmHg, p=0.0254) and IOP of Tg-MyocY437H mice with medium only injection (Tg-Sham, 16.00 ± 0.38 mmHg, p=0.0005). There was no statistically significant difference of IOPs between untreated (Tg, 15.23 ± 0.64 mmHg) and sham (Tg-Sham, 16.00 ± 0.38 mmHg, p=0.6715). Indeed, the IOP of Tg-MyocY437H mice at 2 months after TMSC transplantation (Tg-TMSC, 12.65 ± 0.36 mmHg) reduced to the same level as that of WT (13.03 ± 0.39 mmHg, p=0.9425) and was lower than untreated Tg-MyocY437H (Tg, 14.96 ± 0.61 mmHg, p=0.0042) and sham injected mice (Tg-sham, 15.30 ± 0.21 mmHg, p=0.0006).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Transplanted TMSCs reduce the IOP and increase the outflow facility of Tg-MyocY437H mice.</title><p>(<bold>A</bold>) Day-time IOP was measured in the wildtype mice (WT, n=26), Tg-MyocY437H mice (Tg, n=26), Tg mice treated with basal medium (Tg-Sham, n=26) and Tg mice with TMSC transplantation (Tg-TMSC, n=26). (<bold>B</bold>) Night IOP was measured in WT mice (n=17) and Tg-MyocY437H mice (n=24) before the treatment and 2 months post treatment. Data are presented as mean ± SD. (<bold>C</bold>) Outflow facility was evaluated at 2-month after TMSC transplantation (n=6 eyes/group). (<bold>D</bold>) Representative pictures of anterior OCT show the corneal thickness and anterior chamber angle in the mice at 2 months after transplantation. (<bold>E</bold>) The central corneal thickness was calculated from the OCT images (n=8 eyes/group). Data are presented as mean ± SD. Two-way ANOVA (<bold>A</bold>) or one-way ANOVA (<bold>B,C,E</bold>) followed by Tukey’s multiple comparisons test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, **** p&lt;0.0001.</p><p> <supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw day-time IOP data for <xref ref-type="fig" rid="fig1">Figure 1A</xref>; Raw night IOP data for <xref ref-type="fig" rid="fig1">Figure 1B</xref>; Individual outflow facility for <xref ref-type="fig" rid="fig1">Figure 1C</xref>; Individual central corneal thickness for <xref ref-type="fig" rid="fig1">Figure 1E</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63677-fig1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Genotyping of transgenic Myoc Y437H mice by polymerase chain reaction (PCR).</title><p>Tg-Myoc Y437H mice (+) displayed with PCR products of 249 bp (MyocY437H) and weak band at 610 bp (mouse DNA). The mice with only 610 bp band were transgenic negative mice (-). M: DNA markers.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Representative perfusion outflow data from each mouse group.</title><p>X-axis: perfusion pressure (mmHg), Y-axis: flow rate (μL/min), y is the slope indicating outflow facility (μL/min/mmHg).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig1-figsupp2-v2.tif"/></fig></fig-group><p>Meanwhile, we measured mouse night IOP which was more obviously elevated than day-time IOP as reported before (<xref ref-type="bibr" rid="bib58">Zode et al., 2011</xref>). In consistent with the day-time IOP, there was a significant difference of the baseline night IOP between 4-month-old Tg-MyocY437H mice (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, 17.73 ± 2.25 mmHg) and age-matched WT mice (13.67 ± 2.77 mmHg, p&lt;0.0001). Two months after TMSC transplantation, the night IOP of Tg-MyocY437H mice (11.75 ± 2.83 mmHg) reduced to the same level as that of WT mice (11.55 ± 2.52 mmHg, p=0.9925).</p><p>To further elucidate if TMSCs reduced IOP in Tg-MyocY437H mice via regulating the conventional outflow pathway (the TM and the Schlemm’s canal), we examined the outflow facility of the eyes from all groups. As shown in <xref ref-type="fig" rid="fig1">Figure 1C</xref> and Figure 1-figure supplement 2, Tg-MyocY437H mice displayed higher outflow resistance with lower outflow facility (Tg, 0.010 ± 0.001 μL/min/mmHg), while the WT mice showed higher outflow facility (WT, 0.017 ± 0.001 μL/min/mmHg, p=0.0219). Tg-MyocY437H mice with TMSC transplantation for 2 months showed a significant facilitated outflow (Tg-TMSC, 0.016 ± 0.002 μL/min/mmHg) as compared to untreated (Tg, 0.010 ± 0.001 μL/min/mmHg, p=0.0487) and medium injected Tg-MyocY437H mice (Tg-Sham, 0.009 ± 0.005 μL/min/mmHg, p=0.029). This confirms that TMSCs reduced IOP via improvement of the TM-Schlemm’s canal conventional outflow pathway.</p><p>Since corneal thickness can affect the accuracy of IOP measurement, anterior OCT was adopted to evaluate the thickness of the cornea, and this revealed that the corneas had the same thickness among all groups (<xref ref-type="fig" rid="fig1">Figure 1D–E</xref>). Anterior synechia, which is an important factor for assessing the efficacy and side effect of stem cell transplantation, was not found by OCT examination in the mice with intracameral injection of TMSCs or sham (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p></sec><sec id="s2-2"><title>TMSCs prevent the RGC loss and preserve the RGC function of the Tg-MyocY437H mice</title><p>Preservation and rescuing of RGC function is the goal for the treatment of POAG, so evaluating the function of RGCs is critical in assessing the therapeutic effect of TMSCs on POAG. We used the Celeris (Diagnosys LLC) to examine the pattern electroretinogram (PERG), an optimal approach to detect RGC function. In PERG by Celeris, the P1 amplitude represents the RGC function (<xref ref-type="fig" rid="fig2">Figure 2A–B</xref>). WT mice at 6 month of age had the P1 amplitude at 10.84 ± 0.86 µV in the PERG recording, while 39.4% of the RGC function was lost in 6-mongth old Tg-MyocY437H mice as calculated with the PERG (Tg, P1 = 6.56 ± 0.63 µV, p=0.0001). Two months after TMSC transplantation, nearly 90% of the RGC function of the Tg-MyocY437H mice was preserved (Tg-TMSC, P1 = 9.20 ± 0.45 µV; WT, P1 = 10.84 ± 0.86 µV, p=0.1934) (<xref ref-type="fig" rid="fig2">Figure 2A–B</xref>). Furthermore, we counted the RGC numbers on 5 μm paraffin sections (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). There were 70.48 ± 2.26 RGC cells/mm in the retina of 6-month-old WT mice, and 49.22 ± 1.79 cells/mm in that of 6-month-old Tg-MyocY437H mice with RGC loss (p&lt;0.0001). The RGCs were preserved/rescued by TMSC transplantation in Tg-MyocY437H mice with the RGC number increased to 60.60 ± 1.25 cells/mm (p&lt;0.0001 as compared to untreated Tg-MyocY437H mice). This confirms that TMSC transplantation prevented/rescued the RGC loss and preserved the RGC function in the Tg-MyocY437H mice.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>TMSCs preserve the RGC function and prevent RGC loss in Tg-MyocY437H mice.</title><p>The function of RGCs in the mice was evaluated by pattern electroretinogram (PERG). (<bold>A</bold>) Representative examples of PERG from different groups at 2 months after transplantation. (<bold>B</bold>) Bar graphs of averaged P1 amplitude in PERG (n = 10 eyes/group). (<bold>C</bold>) RGC numbers counted on the retinal sections in each group (n = 12–16 sections/eyes, and 4–6 eyes/group). Data are presented as mean ± SD. One-way ANOVA followed by Tukey’s multiple comparisons test. WT: wild-type mice, Tg: Tg-MyocY437H mice, Tg-Sham: Tg mice with medium injection, Tg-TMSC: Tg mice with TMSC injection.</p><p> <supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Individual P1 amplitude in pattern electroretinogram for <xref ref-type="fig" rid="fig2">Figure 2B</xref>; Individual retinal ganglion cell count of each section for <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63677-fig2-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Transplanted TMSCs rescue RGCs and prevent neurodegeneration in Tg-MyocY437H mice.</title><p>Eye sections stained hematoxylin and eosin show the RGC layer in the eyes. The black INSET boxes in the left picture show the areas from which RGCs were captured so that the RGCs in the whole retina were counted in the central sections that containing optic nerve.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig2-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>TMSCs increase the TM cellularity of the Tg-MyocY437H mice</title><p>To further investigate the mechanisms by which TMSCs reduced IOP and restored outflow facility, we evaluated the TM cellular density in the mouse anterior segment sections. TM cellular density of the Tg-MyocY437H mice has been reported to be decreased due to apoptosis of TM cells in Tg-MyocY437H mice (<xref ref-type="bibr" rid="bib58">Zode et al., 2011</xref>). Collagen IV was used as a marker to define the area of the TM tissue (<xref ref-type="bibr" rid="bib57">Zhu et al., 2016</xref>). We combined the phase contrast black-white images with collagen IV staining to accurately identify the TM region and count the cells within the TM region on the paraffin sections. As shown in <xref ref-type="fig" rid="fig3">Figure 3A–B</xref>, the average number of the cells in the TM region was 35.33 ± 2.50 cells/section in 6-month-old WT mice (n = 10), while 42% and 51% of reduction of the TM cellularity was observed in the age-matched Tg-MyocY437H mice (Tg, 20.33 ± 1.11 cells/section, p&lt;0.0001) and Tg-MyocY437H mice with Sham injection (Tg-Sham, 17.08 ± 1.18 cells/section, p&lt;0.0001), respectively. TMSC transplantation on Tg-MyocY437H mice increased the TM cell number to 28.86 ± 1.46 cells/section (p=0.0028 vs Tg mice, p&lt;0.0001 vs Tg-Sham).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>TMSCs increase the TM cellularity in the Tg-MyocY437H mice.</title><p>(<bold>A</bold>) Evaluation of the cellular density in the mouse TM region. Sections of the anterior segment were immunostained with collagen IV (red) and DAPI (blue). The TM region was determined by bright-field (BF) image together with collagen IV staining in the region between the two white vertical lines. Scale Bars, 50 µm. (<bold>B</bold>) The TM cellularity was averaged (n=12-14/group) and displayed as the number of cells in the TM region per section. Data are presented as mean ± SD. One-way ANOVA followed by Tukey’s multiple comparisons test. <bold>C:</bold> cornea, SC: Schlemm’s canal, TM: trabecular meshwork.</p><p> <supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Individual TM cell count of each section for <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63677-fig3-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig3-v2.tif"/></fig></sec><sec id="s2-4"><title>TMSCs differentiate into TM cells after transplantation in the Tg-MyocY437H mice</title><p>To examine if transplanted TMSCs differentiate into functional TM cells to contribute to the TM cellularity increase and TM function restoration, we labeled TMSCs with DiO and injected the cells into the anterior chamber of Tg-MyocY437H mice. Two months after TMSC transplantation, we detected DiO-labeled green cells at the mouse TM region (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>). Some of the DiO+ TMSCs expressed AQP1 and CHI3L1. Anti-AQP1 antibody detects both mouse and human AQP1 antigen while anti-CHI3L1 antibody used only detects human antigen (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Some of the TMSCs were positive to anti-Ki67 antibody staining (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) indicating the transplanted TMSCs were active in proliferation 2 months after transplantation. TUNEL staining shows there were many TUNEL staining apoptotic cells in the Tg-MyocY437H mouse TM tissue while most of the injected TMSCs and mouse TM tissues were not stained with TUNEL (<xref ref-type="fig" rid="fig4">Figure 4C–D</xref>) indicating the injected TMSCs were alive and protective to the endogenous TM cells.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Transplanted TMSCs differentiate into TM cells and viable up to 2 months post-transplantation.</title><p>(<bold>A</bold>) AQP1/CHI3L1 immunofluorescent staining shows integration of transplanted TMSCs (DiO+, green) into the TM and differentiation of TMSCs into TM cells with expression of AQP1 (red) and CHI3L1 (magenta). (<bold>B</bold>) Ki67 staining shows part of the transplanted TMSCs (green) positive to Ki67 (red) in the TM while few of the TM cells in the Tg-Sham were Ki67+ too. (<bold>C</bold>) TUNEL staining shows some of the corneal cells and TM cells in the Tg mice were positive to TUNEL (apoptosis) while the transplanted TMSCs (green) in the Tg-TMSC were viable as the TMSC population was TUNEL negative. Scale bars, 50 μm. (<bold>D</bold>) Quantification of TUNEL + cells in the TM region of both Tg-MYocY437H mice without treatment (Tg) and with TMSC transplantation (Tg-TMSC). Data are presented as mean ± SD. Student <italic>t</italic>-test. TM: trabecular meshwork.</p><p> <supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Individual TUNEL-positive cells per TM region per section for <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63677-fig4-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig4-v2.tif"/></fig></sec><sec id="s2-5"><title>TMSCs facilitate myocilin secretion and remodel the extracellular matrix (ECM) in the Tg-MYOCY437H mice</title><p>Tg-MyocY437H mouse model is characterized by the retention of misfolded Myoc protein in the ER of the TM cells and reduced secretion of Myoc protein into the aqueous humor (<xref ref-type="bibr" rid="bib58">Zode et al., 2011</xref>), which are associated with the IOP elevation in this mouse model. Immunofluorescent staining on the paraffin sections showed that Myoc protein was not detectable in the TM region of WT mice, but it was obviously expressed in the TM region of the untreated and sham injected Tg-MyocY437H mice (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). However, Myoc expression in the TM region was reduced in the Tg-MyocY437H mice receiving TMSC transplantation (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Western blotting on the limbal tissue confirmed the immunostaining results and showed that TMSC transplantation reduced Myoc protein accumulation in the limbus of the Tg-MyocY437H mice (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In contrast, very low levels of Myoc protein could be detected in the aqueous humor of the Tg-MyocY437H and Tg-Sham mice, but Myoc protein was increased dramatically in the aqueous humor of WT and TMSC transplanted Tg-MyocY437H mice (Tg-TMSCs; <xref ref-type="fig" rid="fig5">Figure 5C</xref>). This indicates that TMSC transplantation can enhance the secretion of Myoc protein from the TM into the aqueous humor in the Tg-MyocY437H mice.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>TMSCs reduce the Myoc retention in the TM tissue, promote the Myoc secretion into the aqueous humor, and reverse the ECM expression in the Tg-MyocY437H mice.</title><p>(<bold>A</bold>) Immunofluorescent staining shows accumulated Myoc in the TM, iris, and ciliary body of the Tg and Tg-sham mice. TMSC transplantation alleviated the aggregation of Myoc in the TM, similar to the WT mice. Scale bars, 50 mm. Western blotting results show: (<bold>B</bold>) The representative bands of Myoc expression in the mouse limbal tissue and the relative Myoc protein levels with b-actin as internal control (n=5). (<bold>C</bold>) The representative bands of Myoc expression in the mouse aqueous humor and the relative Myoc protein levels with b-actin as internal control (n=5). (<bold>D</bold>) The representative bands of the expression of ECM components fibronectin (FN), collagen IV, and elastin in the limbal tissue and the relative ECM protein levels with b-actin as internal control (n=4-6). Data are presented as mean ± SD. One-way ANOVA (<bold>B,C</bold>) or two-way ANOVA (<bold>D</bold>) followed by Tukey’s multiple comparisons test. C: cornea, SC: Schlemm’s canal, TM: trabecular meshwork.</p><p> <supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Relative myocilin protein levels in the corneal limbus for <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</title><p>Relative myocilin protein levels in the aqueous humor of each eye for <xref ref-type="fig" rid="fig5">Figure 5C</xref>; Relative extracellular mactrix protein levels in the corneal limbus for <xref ref-type="fig" rid="fig5">Figure 5D</xref>.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63677-fig5-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig5-v2.tif"/></fig><p>Abnormal deposition of ECM in the TM tissue is known to contribute to IOP elevation. Indeed, increased levels of fibronectin and elastin were found in the limbus of the Tg-MyocY437H and Tg-Sham mice, while collagen IV remained at the similar levels as that in the WT mice (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). However, TMSC transplantation downregulated the expression of fibronectin and elastin in the TMSC-treated Tg-MyocY437H mice to the levels in the WT mice (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). This demonstrates that TMSCs could change the ECM components in the Tg-MyocY437H mice.</p></sec><sec id="s2-6"><title>The effect of TMSCs on ER stress in the TM of Tg-MyocY437H mice</title><p>To determine if TMSC transplantation could reduce ER stress in the TM of the Tg-MyocY437H mice, Western blotting was employed to detect the expression of ER stress markers in the mouse limbal tissue including the TM. The levels of CHOP and GRP78 were significantly increased in the limbal tissue of Tg-MyocY437H and Tg-Sham mice in comparison with the WT mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). The expression of CHOP and GRP78 in the limbal tissue with TMSC injection was not significantly reduced as compared to the Tg-MyocY437H mice.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The effect of TMSCs on ER stress and ultrastructure of the TM in the Tg-Myoc Y437H mice.</title><p>(<bold>A</bold>): Western blotting results show the representative bands of CHOP and GRP78 expression in the mouse limbal tissue and the relative protein levels with β-actin as internal control (n = 6). (<bold>B</bold>) TEM results indicates the ultrastructure of mouse TM tissue (40,000x) with black arrows pointing to the ER. Scale Bar = 500 nm. (<bold>C</bold>) ER size quantification calculated as area (nm<sup>2</sup>)/perimeter (nm) (n = 18–23). Data are presented as mean ± SD. Two-way ANOVA (<bold>A</bold>) or one-way ANOVA (<bold>C</bold>) followed by Tukey’s multiple comparisons test.</p><p> <supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Relative ER stress protein levels in the corneal limbus for <xref ref-type="fig" rid="fig6">Figure 6A</xref>; Relative ER sizes of the TM cells for <xref ref-type="fig" rid="fig6">Figure 6C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63677-fig6-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig6-v2.tif"/></fig><p>We further evaluated the ultrastructure of the TM tissue by transmission electron microscopy (TEM) and measured the size of the ER and calculated as the ER area divided by the perimeter (nm<sup>2</sup>/nm). As shown in <xref ref-type="fig" rid="fig6">Figure 6B</xref> (arrows) and calculation in <xref ref-type="fig" rid="fig6">Figure 6C</xref>, Tg-MyocY437H mice (24.53 ± 2.81 nm<sup>2</sup>/nm) and Tg-Sham mice (24.50 ± 3.79 nm<sup>2</sup>/nm) presented enlarged ER lumen as compared to the WT mice (7.03 ± 0.54 nm<sup>2</sup>/nm). In contrast, the ER lumen of Tg-MyocY437H mice with TMSC transplantation was significantly reduced to 13.78 ± 1.02 nm<sup>2</sup>/nm as compared to untreated (p=0.049) and Sham treated Tg-MyocY437H mice (p=0.0111) and more closely resembled that of WT mice (p=0.1423).</p></sec><sec id="s2-7"><title>TMSCs neither stimulate proliferation nor reverse ER stress of mutant TM cells in vitro</title><p>To further explore the mechanisms behind regenerative effect of transplanted TMSCs in vivo via increasing TM cellularity, enhancing Myoc secretion, remodeling the TM ECM and improving ER stress in the TM, we evaluated the effects of TMSCs on transduced MyocY437H mutant TM cells in vitro to detect the interactions between TMSCs and TM cells. TM cells were transduced with lentivirus which co-expressed GFP and Myoc with Y437H mutation (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Transfected GFP-positive cells were then sorted using flow cytometry and further passaged as a predominantly GFP+ population of TM cells (<xref ref-type="fig" rid="fig7">Figure 7A</xref>) and strongly expressed Myoc (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Cultured TM cells were confirmed via Western blotting by their responsiveness to Dex with increased expression of Myoc (<xref ref-type="fig" rid="fig7">Figure 7B</xref>) after 100 nM Dex treatment for 5 days, one of the characteristics of TM cells (<xref ref-type="bibr" rid="bib24">Keller et al., 2018</xref>). MyocY437H expressing GFP-positive TM cells were cultured alone, with TMSCs in the Transwell inserts (<xref ref-type="fig" rid="fig7">Figure 7C</xref>) or in direct contact with TMSCs and further assessed. Proliferation of the transduced TM cells was evaluated through analysis of incorporation rates of the EdU after 2 hr incubation. Mutant Myoc transduced TM cells showed 6.53 ± 1.19% EdU positivity, while 6.06 ± 1.78% (p=0.8267) and 6.51 ± 1.63% (p=0.9932) of cells were EdU positive when mutant TM cells were co-cultured with TMSCs in a Transwell insert or in direct contact with TMSCs, respectively. This indicated that neither co-culturing nor direct contact with TMSCs could stimulate proliferation of mutant TM cells (<xref ref-type="fig" rid="fig7">Figure 7D</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>TMSCs could not reverse ER stress and stimulate proliferation of Myoc mutant TM cells in vitro.</title><p>(<bold>A</bold>) The TM cells were transduced with recombinant lentivirus encoding GFP and Myoc Y437H mutation. The transduced GFP+ cells were sorted by Flow cytometry and the cultured sorted TM cells were almost 100% with GFP (green) in the cytoplasm. Scale Bars, 100 µm. (<bold>B</bold>) Transduced TM cells with Myoc Y437H mutation expressed high Myoc by western blotting and TM cells had increased Myoc expression after 5-day Dex treatment (TM2, TM3). TM1 did not have increased Myoc expression after Dex treatment so TM1 cells were discarded. (<bold>C</bold>) Schematic illustration shows co-culturing of TMSCs with TM cells for detection of TM cell changes. (<bold>D</bold>) Flow cytometry analysis of EdU incorporation shows neither co-culture nor direct contact with TMSCs for 4 days would affect TM cell proliferation (n=3-5). (<bold>E</bold>) Representative western blotting bands show the levels of ER stress markers and Myoc in the TM cells with or without TMSC co-culturing. (<bold>F</bold>) Relative protein levels with b-actin as internal control (n=3). Data are presented as mean ± SD. One-way ANOVA (<bold>D</bold>) or two-way ANOVA (<bold>F</bold>) followed by Tukey’s multiple comparisons test.</p><p> <supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Percentage of BrdU positive TM cells in different culture conditions for <xref ref-type="fig" rid="fig7">Figure 7D</xref>.</title><p>Relative protein levels by WB in the TM cells with different culture conditions for <xref ref-type="fig" rid="fig7">Figure 7F</xref>.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63677-fig7-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Structure of lentiviral packaging plasmid: pLenti<sup>CMV-Y437H-IRES-GFP</sup>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig7-figsupp1-v2.tif"/></fig></fig-group><p>Next, we evaluated whether TMSCs could reduce ER stress in the Myoc mutant TM cells. As shown in <xref ref-type="fig" rid="fig7">Figure 7E–F</xref>, higher expression of Myoc and ER stress markers GRP78 and CHOP was detected in the mutant TM cells as compared to normal TM cells and TM cells transduced with GFP only. Co-culturing TM cells with TMSCs in the Transwell insert could mimic the interactions seen in vivo between homed TMSCs and TM cells. The co-culturing had little effect on reducing ER stress or promoting Myoc secretion in the mutant TM cells. The expression of GRP78, CHOP, and Myoc in the TM cells after co-culturing was similar to that without co-culturing (<xref ref-type="fig" rid="fig7">Figure 7E–F</xref>).</p></sec><sec id="s2-8"><title>TMSCs differentiate into TM cells responsive to dexamethasone and gain phagocytic function under the ER stress condition in vitro</title><p>One of the mechanisms by which stem cells induce regeneration is differentiation into cells of desired lineage to compensate for deficient cells in the injured tissue. We previously reported that TMSCs (<xref ref-type="bibr" rid="bib14">Du et al., 2013</xref>; <xref ref-type="bibr" rid="bib50">Xiong et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>) and ADSCs (<xref ref-type="bibr" rid="bib56">Zhou et al., 2020</xref>) could differentiate into TM cells and express TM markers after homing to the TM tissues. However, the environment of the Tg-MyocY437H mouse TM where TMSCs stayed is different. The TM tissue of Tg-MyocY437H mice possesses ER stress with ECM changes (<xref ref-type="bibr" rid="bib21">Kasetti et al., 2016</xref>). Understanding whether TMSCs can differentiate to TM cells under ER stress condition could help to elucidate how TMSCs regulate IOP in the Tg-MyocY437H mice. We co-cultured TMSCs together with the transduced Myoc mutant TM cells in a Transwell system (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). CHI3L1 expression (<xref ref-type="fig" rid="fig8">Figure 8B</xref>) was significantly increased in the TMSCs after co-culturing with normal TM cells (TM+TMSC) or with MyocY437H mutant TM cells (Y437H TM+TMSC), in comparison to TMSCs without co-culture (TMSC). After another 7 day culture of the TMSCs in the presence of 100 nM Dex, the expression of Myoc (<xref ref-type="fig" rid="fig8">Figure 8C</xref>) was significantly increased in the TMSCs co-cultured with TM cells (TM+TMSC) or mutant TM cells (Y437H TM+TMSC) while the Myoc expression was almost undetectable without co-culture (TMSC). TMSCs co-cultured with normal and Myoc mutant TM cells gained the phagocytic function, evidenced by ingesting fluorescent labeled bioparticles (<xref ref-type="fig" rid="fig8">Figure 8D–E</xref>). Taken together, TMSCs are able to differentiate into TM cells responsive to dexamethasone treatment and possessing the phagocytic function under ER stress environment.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>TMSCs differentiate into TM cells in vitro under ER stress environment.</title><p>(<bold>A</bold>) Schematic illustration shows co-culturing of TMSCs with TM cells for detection of TMSC changes. (<bold>B</bold>) The expression of TM cell marker CHI3L1 was upregulated in the TMSCs after 10 days of co-culturing with normal TM cells or MyocY437H mutant TM cells (n = 3). (<bold>C</bold>) After co-culturing for 10 days, the co-cultured TM cells in the Transwell insert were removed, and TMSCs were further treated with Dex for another 7 days. The levels of Myoc were detected by western blotting and quantified (n = 3). (<bold>D</bold>) After co-culturing of TMSCs with the TM cells or Myoc Y437H mutant TM cells in the Transwell insert for 10 days, the phagocytic ability of the TMSCs was evaluated by ingestion of bioparticles shown green in the cytoplasm. Scale Bars, 50 µm. (<bold>E</bold>) Percentage of phagocytic cells averaged from 10 different views. Data are presented as mean ± SD. One-way ANOVA followed by Tukey’s multiple comparisons test.</p><p> <supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Relative CHI3L1 protein levels by WB in TMSC with different culture conditions for <xref ref-type="fig" rid="fig8">Figure 8B</xref>.</title><p>Relative myocilin protein levels by WB in TMSC with different culture conditions for <xref ref-type="fig" rid="fig8">Figure 8C</xref>; Individual percentage of phagocytic cells per field for <xref ref-type="fig" rid="fig8">Figure 8E</xref>.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63677-fig8-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig8-v2.tif"/></fig></sec><sec id="s2-9"><title>TMSCs had upregulated gene expression related to TM ECM maintenance and TM regeneration</title><p>We analyzed the transcriptomes of three individual TMSCs and fibroblasts from different donors since we previously reported that fibroblasts were not able to home to the TM and to regenerate the TM tissue (<xref ref-type="bibr" rid="bib14">Du et al., 2013</xref>; <xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>). We observed an upregulation of genes related to maintenance of TM ECM, integrity and motility like <italic>integrin subunit alpha 3 (ITGA3), CHI3L1, vitronectin (VTN), lysyl oxidase (LOX), follistatin (FST), and collagen type IV alpha six chain</italic> (<italic>COL4A6</italic>) (<xref ref-type="bibr" rid="bib30">Liton et al., 2006</xref>) in TMSCs as compared to fibroblasts (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). Top three upregulated pathways in TMSCs related to increased TM ECM interaction were (1) focal adhesion pathway including <italic>VTN</italic>, <italic>collagen type IV alpha five chain</italic> (<italic>COL4A5</italic>), <italic>myosin light chain kinase</italic> (<italic>MYLK</italic>), <italic>platelet derived growth factor D</italic> (<italic>PDGFD</italic>), and <italic>COL4A6</italic>; (2) PI3K-Akt signaling pathway including <italic>VTN, COL4A5, PDGFD</italic>, and <italic>COL4A6</italic>; and (3) ECM-receptor interaction pathway including <italic>VTN, COL4A5, heparan sulfate proteoglycan core protein</italic> (<italic>HSPG2</italic>), and <italic>COL4A6</italic> (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). By interactome analysis for neuroprotective property of TMSCs, we identified many genes related to neuroprotection, including <italic>neutralized E3 ubiquitin protein ligase 1</italic> (<italic>NEURL1</italic>) (formation of functional synapses), <italic>neurofascin</italic> (neurite extension, axonal guidance, synaptogenesis, myelination, and neuron-glial cell interactions), <italic>neuroligin-1/3/4X</italic> (synapse function and synaptic signal transmission). Reactome analysis identified proteins involved in glutamatergic, dopaminergic, GABAergic pathways activated in TMSCs (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). Pathway enrichment analysis identified neurotrophin signaling pathway and PI3-Akt signaling pathway to be the major pathways related to the neuroprotection of RGCs.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Transcriptome analysis of TM regeneration and neuroprotection genes among TMSC and fibroblasts.</title><p>(<bold>A</bold>) Heatmap shows gene expression profile of TMSCs as compared to fibroblasts for genes involved in maintenance of TM extracellular matrix (ECM), TM integrity and motility, (false discover rate (FDR) &lt; 1%, p&lt;0.01). Scale, bright red squares: highest gene expression levels, bright blue squares: lowest gene expression levels. (<bold>B</bold>) Interactome analysis shows activation of different neuroprotection pathways in TMSCs as obtained by RNA sequencing analysis. Interactome networks were generated using STRING v11.</p><p> <supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Related gene expression increase (p&lt;0.05) in three individual TMSCs as compared to fibroblasts for <xref ref-type="fig" rid="fig9">Figure 9A</xref>.</title><p>Related neuroprotection related gene expression increase (p&lt;0.05) in three individual TMSCs as compared to fibroblasts for <xref ref-type="fig" rid="fig9">Figure 9B</xref>.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63677-fig9-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig9-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study we demonstrated, as illustrated in the graphical abstract <xref ref-type="fig" rid="fig10">Figure 10</xref>, that human TMSCs transplanted to the anterior chamber of transgenic Myoc Y437H mutant mice differentiated to the cells expressing TM cell markers at TM region and alleviated many of the parameters associated with glaucoma in the validated POAG mouse model. Specifically, transplantation of TMSCs reduced the IOP, increased the outflow facility, restored the RGC function with significantly improved pattern ERG and preserved the RGCs. With TMSC transplantation, the TM cellularity in the Tg-MyocY437H mice dramatically increased and the ECM components fibronectin and elastin dramatically reduced in comparison with untreated and sham injected Tg-MyocY437H mice. Although ER stress marker expression in the TM tissue was not significantly reduced after TMSC transplantation, the secreted Myoc into the aqueous humor was significantly increased, while non-secreted Myoc in the TM tissue was decreased to normal range compared to untreated and sham-treated Tg-MyocY437H mice. In vitro co-culturing study indicated that TMSCs could differentiate into Dex-responsive TM cells with phagocytic function in the presence of normal TM cells or transduced TM cells with Myoc Y437H mutation. The TMSCs did not reverse ER stress of cultured MyocY437H mutant TM cells in the co-culture platform. RNAseq analysis showing upregulation of genes related to TM regeneration including maintenance of TM integrity, motility, and ECM interaction in TMSCs as compared to fibroblasts might explain that TMSCs induce regeneration in the Tg-MyocY437H mice via modulation of ECM, promotion of TM integrity and motility, and increasing the oxidative stress defense mechanism of TM cells. In contrast, fibroblasts having much lower expression of the abovementioned genes were unable to produce any regenerative effect as we showed previously (<xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>).</p><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Graphical abstract.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63677-fig10-v2.tif"/></fig><p>Our previous studies have shown that the response to ER stress inducers is different between TMSCs and TM cells (<xref ref-type="bibr" rid="bib48">Wang et al., 2019</xref>), and TMSCs can differentiate into TM cells after homing in and retained in normal TM of WT mice (<xref ref-type="bibr" rid="bib14">Du et al., 2013</xref>) and in the laser-damaged TM for regeneration (<xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>). However, the microenvironment for the stem cells such as oxygen concentration, PH value, osmotic pressure, proteases and cytokines, all affects the maintenance, survival, and regeneration properties of stem cells (<xref ref-type="bibr" rid="bib45">Urban, 2002</xref>; <xref ref-type="bibr" rid="bib49">Wuertz et al., 2008</xref>). It was therefore crucial to confirm whether TMSCs could convert to the TM cells in the Tg-MyocY437H mice with ER stress in the TM tissue. We demonstrated that TMSCs could differentiate into TM cells expressing the TM cell marker CHI3L1 (<xref ref-type="bibr" rid="bib13">Du et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Kelley et al., 2009</xref>; <xref ref-type="bibr" rid="bib48">Wang et al., 2019</xref>) and possessed phagocytic ability 10 days after co-culturing with the transduced Myoc Y437H mutant TM cells. Phagocytic function of TM cells is responsible for ECM turnover and maintenance of the outflow pathway by removing cell debris, which is crucial for regulation of IOP. Moreover, the differentiated TMSCs were responsive to dexamethasone treatment with increased expression of Myoc, one of the important characteristics of TM cells (<xref ref-type="bibr" rid="bib24">Keller et al., 2018</xref>). It indicates that TMSCs can successfully differentiate to functional TM cells under ER stress condition.</p><p>The homeostasis of the TM tissue is known to be important for maintaining IOP in the normal range (<xref ref-type="bibr" rid="bib47">Vranka et al., 2015</xref>). Some pathological stimuli can elevate IOP by breaking down TM ECM homeostasis, which results in the excessive accumulation of ECM composition and insufficient degradation of ECM in the TM tissue, thereby decreasing the outflow facility (<xref ref-type="bibr" rid="bib2">Acott and Kelley, 2008</xref>). ER stress arising from mutant Myoc aggregates in the ER can destroy assembly procedures of ECM proteins in the TM cells. The ECM components, such as fibronectin, elastin, and collagen IV were increased in the TM tissue due to abnormal ER function and pathological cellular status in the Tg-MyocY437H mice (<xref ref-type="bibr" rid="bib21">Kasetti et al., 2016</xref>). Conversely, excessive ECM can aggravate ER stress in the TM cells, which can form a negative feedback to keep the chronic ER stress existing in the Tg-MyocY437H mice (<xref ref-type="bibr" rid="bib22">Kasetti et al., 2017</xref>). We found that transplantation of TMSCs can reverse the expression of fibronectin and elastin to the normal levels in the Tg-MyocY437H mouse TM tissue. Although the reduction of ER stress marker expression after TMSC transplantation was not significant, the expression levels of Myoc reduced in the TM tissue and increased in the aqueous humor, and a large number of cells displayed normal ultrastructure without swollen ER in the TM region of the Tg-MyocY437H mice with TMSC transplantation. These observations suggest that differentiated healthy TM cells from TMSCs replaced the mutant TM cells and remodeled the ECM, improved the function of the diseased TM tissue, which increased the outflow facility and reduced IOP. A previous report (<xref ref-type="bibr" rid="bib57">Zhu et al., 2016</xref>) indicated that transplantation of TM cells derived for iPSCs stimulated the endogenous TM cells to proliferate to increase the TM cellularity and reduce IOP. Although the cells and underlying mechanisms for the treatment in their study are different from ours, increased amount of TM cells was found in both studies. It indicates that restoration of TM cellularity and remodeling of the TM ECM are crucial for cell-based therapy for glaucoma.</p><p>Mesenchymal stem cells have been shown to reduce IOP in a laser-induced rat glaucoma model (<xref ref-type="bibr" rid="bib31">Manuguerra-Gagné et al., 2013</xref>). The activation of progenitor cells in the ciliary body which can migrate and differentiate into TM cells in the damaged tissue might be induced by laser photocoagulation or injected cells. Further research is needed to elucidate whether TMSCs can recruit the endogenous stem cells to synergistically repair the TM tissue.</p><p>Loss of RGCs is responsible for the impairment of visual field and loss of visual acuity in POAG patients (<xref ref-type="bibr" rid="bib38">Rolle et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Shoji et al., 2017</xref>). Preserving the RGCs is as important as reducing IOP in treatment for glaucoma (<xref ref-type="bibr" rid="bib39">Sena and Lindsley, 2017</xref>; <xref ref-type="bibr" rid="bib41">Stern et al., 2018</xref>). It is also a critical parameter to evaluate whether stem cell-based therapy is suitable for the management of glaucoma (<xref ref-type="bibr" rid="bib34">Pearson and Martin, 2015</xref>). Elevation of IOP and subsequent loss of RGCs were observed in the Tg-MyocY437H mice (<xref ref-type="bibr" rid="bib58">Zode et al., 2011</xref>). Therefore, attention was also paid to the therapeutic effect of TMSCs on protection of RGC function. In this study, 90% of RGC function was saved 2 months after TMSC transplantation, while only 60% of RGC function remained in the 6-month-old Tg-MyocY437H mice without treatment as compared to age-matched WT mice. It indicates that TMSCs can prevent the RGCs from degeneration resulted from IOP elevation. Nevertheless, 10% loss of RGC function may be attributed to the delayed effect of TMSCs on reducing IOP in this glaucoma model, in which IOP starts to elevate from 3 months of age while TMSCs were transplanted at 4 months and the IOP reduction was observed at 5 months. Therefore, whether earlier intervention can achieve more RGC survival needs further investigation.</p><p>We previously reported that TMSCs can regenerate the damaged TM tissue while corneal fibroblasts did not repair the damaged TM tissue (<xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>). Corneal fibroblasts did not express stem cell markers, such as NESTIN or OCT 4, which TMSCs were positive to and the fibroblasts did not home to and anchoring to the TM region after intracamerally injection (<xref ref-type="bibr" rid="bib14">Du et al., 2013</xref>; <xref ref-type="bibr" rid="bib50">Xiong et al., 2020</xref>). All these suggest that TMSCs and corneal fibroblasts are distinctive in biological characteristics and behavior. Thus, we compared the transcriptomes between TMSCs and corneal fibroblasts.</p><p>Our transcriptome analysis indicates some ECM related genes and genes associated with ECM modulation pathways like PI3K-Akt signaling pathway, focal adhesion pathway, ECM-receptor interaction pathway (<xref ref-type="bibr" rid="bib46">Villegas et al., 2013</xref>) were highly expressed in TMSCs. Whether TMSCs directly participate in ECM remodeling through aforementioned ECM related genes and pathways after transplantation remains to be elucidated. Since we detected that some TMSCs differentiated into TM cells after homing to the TM region, we speculate that both the differentiated TM cells from TMSCs and undifferentiated TMSCs participate in the TM ECM modulation. CHI3L1 has been involved in tissue remodeling and important for normal functioning of TM (<xref ref-type="bibr" rid="bib27">Kumar et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Kumar et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Zhou et al., 2020</xref>). Integrins are crucial for ECM organization in the TM and help in anchoring of stem cells to the site of injury for regeneration (<xref ref-type="bibr" rid="bib17">Gagen et al., 2014</xref>; <xref ref-type="bibr" rid="bib50">Xiong et al., 2020</xref>). The upregulation of CHI3L1 and integrins in TMSCs as compared to fibroblasts further strengthen their regenerative role in the Tg-MyocY437H glaucoma model, although the CHI3L1 expression in TMSCs is much lower than that in TM cells.</p><p>Some of the genes which are upregulated in TMSCs have been shown to impart neuroprotective functions. CACNA1A uncovered in TMSC transcriptome (involved in dopaminergic, GABAergic, serotonergic and glutamatergic synapse) is responsible for communication between neurons by ion exchange and mutations in this gene results into neurological disorder (<xref ref-type="bibr" rid="bib33">Ophoff et al., 1996</xref>). Similarly, KCNJ5 (GIRK2) are G-protein-gated potassium channels which are employed in control of hypothermia induced by activation of GABAergic, muscarinic, kappa opioid, adenosine, and serotonergic receptors (<xref ref-type="bibr" rid="bib11">Costa et al., 2005</xref>). We speculate that the preservation of RGCs and their function in Tg-MyocY437H model by TMSCs is mainly due to reduced IOP, but these neuroprotective proteins through paracrine secretion by TMSCs might be also involved in the neuroprotective process. Further study is required to uncover it.</p><sec id="s3-1"><title>Conclusion</title><p>Transplanted TMSCs can integrate into the TM tissue and differentiate into functional TM cells that can repopulate the TM tissue, remodel the TM ECM, and reinstate the TM homeostasis to restore the outflow facility, eventually reducing IOP and preserving RGCs and their function in the Tg-MyocY437H mouse model of POAG. Glaucoma with Myoc Y437H gene mutation as a subtype of POAG contains common pathophysiology of POAG that is reduced TM cellularity, which causes abnormal deposition of the ECM and increases IOP and damages the RGCs. Therefore, these results open an important avenue of a novel stem-cell-based strategy to eventually treat human open-angle glaucoma.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or <break/>resource</th><th valign="top">Designation</th><th valign="top">Source or <break/>reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Genetic reagent (<italic>Mus musculus</italic>)</td><td valign="top">Transgenic <break/>Myoc Y437H mice</td><td valign="top">Courtesy of Dr. Gulab Zode <xref ref-type="bibr" rid="bib58">Zode et al., 2011</xref></td><td valign="top"/><td valign="top">North Texas Eye Research Institute</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Trabecular Meshwork Stem Cells <break/>(TMSCs)</td><td valign="top">This paper</td><td valign="top"/><td rowspan="3" valign="top">Cells isolated from both male and female donors, characterized, and maintained in Du lab</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Trabecular Meshwork Cells <break/>(TM cells)</td><td valign="top">This paper</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Corneal fibroblasts</td><td valign="top">This paper</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Mycoplasma contamination detection kit</td><td valign="top">InvivoGen</td><td valign="top">Cat# rep-pt1</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Collagen IV <break/>(Rabbit polyclonal)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# SAB4500369 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10743858">AB_10743858</ext-link></td><td valign="top">IF(1:100) <break/>WB(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-AQP1 (Mouse monoclonal)</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">Cat# sc25287 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_626694">AB_626694</ext-link></td><td valign="top">IF (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-human CHI3L1 (Goat polyclonal)</td><td valign="top">R and D Systems</td><td valign="top">Cat# AF2599, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2291883">AB_2291883</ext-link></td><td valign="top">IF(1:50), WB (1:250)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Ki67 (Rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab15580 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_443209">AB_443209</ext-link></td><td valign="top">IF(1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-myocilin (Rabbit polyclonal)</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">Cat# Sc137233 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2148737">AB_2148737</ext-link></td><td valign="top">IF(1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-myocilin <break/>(Mouse monoclonal)</td><td valign="top">R and D Systems</td><td valign="top">Cat# MAB3446 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2148649">AB_2148649</ext-link></td><td valign="top">WB(1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-fibronectin (Rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# b23750 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_447655">AB_447655</ext-link></td><td valign="top">WB(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-elastin (Mouse monoclonal)</td><td valign="top">Millipore</td><td valign="top">Cat#: MAB2503 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2099602">AB_2099602</ext-link></td><td valign="top">WB(1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">CHOP <break/>(Mouse monoclonal)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat#: 2895 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2089254">AB_2089254</ext-link></td><td valign="top">WB(1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">GRP78 <break/>(Mouse monoclonal)</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">Cat# sc-376768 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2819145">AB_2819145</ext-link></td><td valign="top">WB(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">β-actin (Mouse monoclonal)</td><td valign="top">Thermo Fisher</td><td valign="top">Cat# MA5-15739 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10979409">AB_10979409</ext-link></td><td valign="top">WB(1:5000)</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLentiCMV-GFP (plasmid)</td><td valign="top">AddGene</td><td valign="top">Cat# 17448</td><td valign="top">Lentiviral construct</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pCAGIG2 (plasmid)</td><td valign="top">AddGene</td><td valign="top">Cat# 111159</td><td valign="top">IRES-EGFP cassette</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pcDNA3 Myoc Y437H</td><td valign="top">Courtesy of Dr. John Hulleman <xref ref-type="bibr" rid="bib54">Zadoo et al., 2016</xref></td><td valign="top"/><td valign="top">UT Southwestern</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Mouse DNA_F</td><td valign="top">Thermo Fisher</td><td valign="top">PCR primers</td><td valign="top">GACTAAGGCAAGAAAATGAGAATC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Mouse DNA _R</td><td valign="top">Thermo Fisher</td><td valign="top">PCR primers</td><td valign="top">CCTCTCCACTCCTGAGATAGC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Mutant Myoc_F</td><td valign="top">Thermo Fisher</td><td valign="top">PCR primers</td><td valign="top">ACAAAGGCAGGGTCGAGAAGACAGG</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Mutant Myoc_R</td><td valign="top">Thermo Fisher</td><td valign="top">PCR primers</td><td valign="top">TTCCCACCTCTCTCTCCCCATGAGA</td></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">In Situ Cell Death Detection Kit</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# 12156792910</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">RNeasy Mini Kit</td><td valign="top">Qiagen</td><td valign="top">Cat# 74106</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">cDNA Reverse Transcription Kit</td><td valign="top">Life Technologies</td><td valign="top">Cat# 4368813</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Power SYBR Green PCR Master Mix</td><td valign="top">Life Technologies</td><td valign="top">Cat# 4368708</td><td valign="top"/></tr><tr><td valign="top">Chemical compound</td><td valign="top">opsonized Alexa 546-conjugated <italic>S. aureus</italic> bioparticles</td><td valign="top">Thermo Fisher</td><td valign="top">Cat# A10010</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">String V11</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://string-db.org/">https://string-db.org/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_005223">SCR_005223</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">FlowJo version 10</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/">https://www.flowjo.com/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">ImageJ</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://fiji.sc/">https://fiji.sc/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002285">SCR_002285</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Graphpad Prism 8</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Espion version 6</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://diagnosysllc.com">http://diagnosysllc.com</ext-link></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">DAPI</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# D9542</td><td valign="top">Stain: 1 µg/ml</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>Four-month-old wildtype (WT) C57BL/6J mice were purchased from Jackson Laboratory as the normal control, and Tg-MyocY437H mice originated from C57BL/6J mice were kindly gifted by Dr. Gulab Zode (North Texas Eye Research Institute, Texas) and transferred to University of Pittsburgh. All the experiments conducted on the animals were approved by the University of Pittsburgh Institutional Animal Care and Use Committee (protocol 18022317) and complied with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Both WT C57B/6J and Tg-MyocY437H C57B/6J mice were bred in the animal facility at University of Pittsburgh. Mouse DNAs were isolated by biopsy from mouse ears for genotyping using the primers with sequences shown in the Key Resource Table (Mutant Myoc_F and _R; and Mouse DNA_F and _R). Mice with PCR product at 249 bp were regarded as carrying the Myoc mutation and a 610 bp product was used to confirm the content of mouse DNA (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p></sec><sec id="s4-2"><title>Intracameral transplantation of TMSCs and IOP measurement</title><p>Human TMSCs were isolated and passaged as previous reported (<xref ref-type="bibr" rid="bib13">Du et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Wang et al., 2019</xref>). Two TMSC strains from two different donors at passage three or four were used for cell injection. TMSCs were prelabeled with DiO at 50 μg/ml for 30 min (<xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>) and thoroughly washed with DMEM/F12 and resuspended in the medium at the concentration of 1.67 × 10<sup>7</sup>/ ml for injection. Mice were divided into four groups: Wildtype group (WT, n = 26), age-matched Tg-MyocY437H mice (Tg, n = 26), Tg mice with intracameral injection of the basal medium (Tg-Sham, n = 26) and Tg mice with TMSC transplantation (Tg-TMSC, n = 26). Intracameral injection was following previous published procedures (<xref ref-type="bibr" rid="bib14">Du et al., 2013</xref>; <xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>) with modifications. In brief, mice at the age of 4 months were anesthetized with ketamine-xylazine by intraperitoneal injection. A total of 3 μl of medium with 5 × 10<sup>4</sup> TMSCs or medium only (sham) were injected into the mouse anterior chamber using a 33-gauge needle connected to a 25 μl Hamilton syringe. An I-care tonometer was used to measure mouse IOP (TonoLab; Colonial Medical Supply, Windham, NH). Day-time IOP measurements were performed between 1:00 pm and 3:00 pm. Day-time IOP measurement before injection served as baseline and was conducted at different time points at week 1, week 2, month 1, and month 2 after transplantation. The night IOP was measured between 11 pm and 1 am and included two time points that were pre-transplantation as baseline and 2 months post-transplantation.</p></sec><sec id="s4-3"><title>Measurement of outﬂow facility</title><p>The procedure for measuring outﬂow facility was described previously (<xref ref-type="bibr" rid="bib28">Lei et al., 2011</xref>; <xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Zhou et al., 2020</xref>). All the outflow measurements on mouse eyes were finished within 6 hr after enucleation. Eyes were irrigated with phosphate buffer saline (PBS) at constant pressures of 4, 8, 15, and 25 mmHg and outflow was recorded at least 15 min at each pressure after the pressure was stable. Twelve eyes from each group were then perfused. Outﬂow facility (μL/min/mmHg) was calculated using the Goldmann equation (<xref ref-type="bibr" rid="bib28">Lei et al., 2011</xref>). Data were accepted when R<sup>2</sup> was greater than 0.95 and data from at least six eyes per group were analyzed and averaged.</p></sec><sec id="s4-4"><title>Transmission electron microscopy</title><p>Transmission electron microscopy (TEM) was used to evaluate the ultrastructure of the TM as described previously (<xref ref-type="bibr" rid="bib51">Yun et al., 2014</xref>). After removing the iris, the limbus tissues (n = 3) from each group were ﬁxed in Karnovsky’s ﬁxative and divided into quarters of each tissue. Subsequently, the tissues were dehydrated and embedded in Epon and 65 nm Ultrathin sections were cut, stained with uranyl acetate (Electron Microscopy Sciences) and Reynold’s lead citrate (Fisher). Sections were photographed at 80 kV on a Jeol 1011 TEM for analysis. For evaluation of ER size, the boundary of ER on each TEM image was delineated and ER region was colored by photoshop (Adobe). Then, the area and perimeter of the ER was calculated by Image pro plus (Media Cybernetics). The ER size was displayed as ER area/ER perimeter (nm<sup>2</sup>/nm).</p></sec><sec id="s4-5"><title>Counting RGCs</title><p>The mouse eyes were enucleated and fixed in 4% paraformaldehyde overnight followed by subsequently dehydration and embedding in paraffin. A total of 5 μm sagittal sections were stained with hematoxylin and eosin. The sections adjacent to the optic nerve were used to capture the retina images using a ×40 oil objective in a microscopy (Olympus). The number of cells in the RGC layer was counted throughout the whole retina on four consecutive sections from each eye, and normalized to mean nuclei per mm.</p></sec><sec id="s4-6"><title>Immunostaining and counting of TM cellularity</title><p>The mouse eyes were fixed in 4% paraformaldehyde overnight and embedded in paraffin. After dewaxing, rehydration, heat-induced epitope retrieval and blocking with 10% heat-inactivated goat serum, sections were incubated with primary antibodies to myocilin, CHI3L1 (R and D Systems), collagen IV, Ki67(Abcam), AQP1(Santa Cruz) overnight at 4°C. After three washes with PBS, corresponding fluorescent secondary antibodies and 4′,6-diamidino-2-phenylindole (DAPI) were applied to the sections for 1 hr. After five washes, slides were mounted and imaged using a confocal microscope (Olympus IX81) and analyzed on FV10-ASW4.2 Viewer (Olympus). For measuring TM cellularity, primary antibody against collagen IV, together with phase-contrast images, were used to define the TM region in the sections. Cell nuclei stained with DAPI within the TM region were counted under FV10-ASW4.2 Viewer. Images of at least 10 ﬁelds per group were photographed, and the number of cell nuclei per ﬁeld was counted and averaged.</p></sec><sec id="s4-7"><title>TUNEL analysis</title><p>The cell death detection kit (In Situ Cell Death Detection Kit, Sigma-Aldrich) was used to perform TUNEL analysis according to manufacturer's protocol. The cell nuclei on the section were stained with DAPI and images were captured under a confocal microscope (Olympus IX81). 10–14 sections from three eyes in each group were stained and analyzed for TMSC viability 2 months after transplantation.</p></sec><sec id="s4-8"><title>Phagocytosis assay</title><p>Cells were incubated with opsonized Alexa 546-conjugated <italic>S. aureus</italic> bioparticles (ThermoFisher) at a ratio of 20 bioparticles per cell at 37°C for 1 hr. After incubation, the cells were washed with PBS, trypsinized and transferred to another 6-well plated with coverslips at the bottom to get rid of any noningested bioparticles. After attachment, cells were ﬁxed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, and incubated with phalloidin conjugated with AlexFluor-647 and DAPI. Cellular phagocytosis of bioparticles which were ingested by the cells was observed within the cytoplasm and photographed under a confocal microscope (Olympus). At least 10 individual views per condition were counted and averaged. The phagocytic ability was calculated as following:<disp-formula id="equ1"><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">%</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>P</mml:mi><mml:mi>h</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>p</mml:mi><mml:mi>h</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>C</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mstyle></mml:math></disp-formula></p></sec><sec id="s4-9"><title>Construction of recombinant lentivirus Myoc Y437H/GFP</title><p>Recombinant Lentiviral Vector encoding Myoc Y437H was constructed from plasmids pLenti<bold><sup>CMV-GFP</sup></bold>(Addgene 17448) (<xref ref-type="bibr" rid="bib9">Campeau et al., 2009</xref>), p<bold><sup>CAGIG2</sup></bold> (Addgene 111159) (<xref ref-type="bibr" rid="bib32">Matsuda and Cepko, 2004</xref>) and pcDNA3<sup>Myoc Y437H</sup> (<xref ref-type="bibr" rid="bib54">Zadoo et al., 2016</xref>) (a kind gift from Dr. Hulleman at UT Southwestern). Briefly, pLenti <sup>CMV-GFP-Puro</sup> was digested with BamHI and SalI (NEB) to remove GFP cassette and served as the vector backbone, which was utilized to generate lentivirus encoding plasmid (pLenti<sup>CMV-IRES-GFP</sup>) by insertion of IRES-EGFP cassette (obtained from p<bold><sup>CAGIG2</sup></bold>) into it. The cDNA sequence containing Tyr437His mutation was amplified from pcDNA3<sup>Myoc Y437H</sup> by using the primers: Forward 5'-<named-content content-type="sequence">ACACCGACTCTAGAGATGAGGTTCTTCTGTGCACGT</named-content>-3’ and Reverse 5 '-<named-content content-type="sequence">GGCGACCGGTGGATCTCACATCTTGGAGAGCTTGATG</named-content>- 3'. It was subsequently cloned into BamHI site in the pLenti <sup>CMV-IRES-GFP</sup> by In-Fusion cloning kit (Clontech, 639649) to generate lentiviral packaging plasmids(pLenti<sup>CMV-Y437H-IRES-GFP)</sup>, which were co-transfected with ViraPower<sup>R</sup> Lentiviral Packaging Mix (Invitrogen) in to 293 T cells using Lipofectamine 3000 Reagent (Invitrogen, L3000015) for Lentivirus assembly. The supernatant of transfected cells taken at day five was then concentrated with Lenti-X Concentrator (TakKaRa, 631232) for the collection of recombinant lentiviruses encoding the mutant myocilin (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>).</p></sec><sec id="s4-10"><title>Cell culture and lentivirus transduction</title><p>Human cell culture was approved by the Committee for Oversignt of Research and Clinical Training Involving Decedents (CORID No. 161). The human corneas from both male and female donors containing TM tissue were obtained from the Center for Organ Recovery and Education (Pittsburgh, PA) and used for isolation of TM cells, TMSCs, and corneal fibroblasts. The cells were cultured and passaged as previously reported (<xref ref-type="bibr" rid="bib12">Du et al., 2009</xref>; <xref ref-type="bibr" rid="bib13">Du et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Wang et al., 2019</xref>). Human TM cells were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM)/F12 with 10% fetal bovine serum (FBS) and identified as responsiveness to 100 nM Dex treatment for 5 days with increased Myoc expression by Western blotting as recommended by a consensus of investigators in the field (<xref ref-type="bibr" rid="bib24">Keller et al., 2018</xref>) and as we previously reported (<xref ref-type="bibr" rid="bib50">Xiong et al., 2020</xref>). Human TMSCs were cultured in Opti-MEM (Invitrogen) with 5% FBS and a variety of supplements (<xref ref-type="bibr" rid="bib13">Du et al., 2012</xref>) and identified as expression of stem cell markers CD73, CD90, CD105, CD166 by flow cytometry and confirmation of clonal formation and multipotency including the ability to differentiate into TM cells (<xref ref-type="bibr" rid="bib13">Du et al., 2012</xref>; <xref ref-type="bibr" rid="bib27">Kumar et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>). Human fibroblasts were cultured in (DMEM)/F12 with 10% FBS and were negative to those stem cell markers without clonal formation (<xref ref-type="bibr" rid="bib5">Basu et al., 2014</xref>; <xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>). The TMSCs and TM cells at passages 3–4 and fibroblasts at passages 4–7 were used for the experiments in this study. All the cultured cells were tested negative for mycoplasma contamination using the Mycoplasma Detection Kit (Invivogen, San Diego, CA).</p><sec id="s4-10-1"><title>Lentivirus transduction</title><p>Primary TM cells at passage 3% and 70% confluence were transduced with lentivirus encoding both mutant Myoc and GFP protein or GFP alone as a control at a multiplicity of infection (MOI) 3. Polybrene was used at 6 µg/ml to increase transduction efficiency. GFP positive cells were sorted through Flow cytometry (BD Biosciences, San Jose, CA) 3 days after transduction and passaged for the following studies.</p></sec><sec id="s4-10-2"><title>Co-culture of TMSCs and TM cells</title><p>For analyzing the effect of TMSCs on reversing ER stress and relieving accumulation of mutant Myoc in transduced TM cells, 5 × 10<sup>4</sup> TMSCs were seeded in the upper chamber of 6-well Corning Transwell inserts, while 5 × 10<sup>4</sup> normal TM cells or transduced TM cells with MyocY437H mutation were maintained at the bottom of the plates. To determine whether TMSCs could stimulate proliferation of mutant TM cells, 5 × 10<sup>4</sup> TMSCs were plated directly on pre-plated 5 × 10<sup>4</sup> Myoc mutant TM cells or TMSCs were in Transwell inserts as just described and cells were cocultured for 4 days. To determine if TMSCs could differentiate into TM cells under ER stress environment, 5 × 10<sup>4</sup> mutant MyocY437H TM cells in the inserts were cocultured with 5 × 10<sup>4</sup> TMSCs for 10 days. Then, the upper inserts containing mutant TM cells were removed, the TMSCs in the bottom compartment were utilized for phagocytosis assay or further cultured with dexamethasone (100 nM) for another 7 days.</p></sec></sec><sec id="s4-11"><title>EdU incorporation and flow cytometry analysis</title><p>To determine whether TMSCs influence the proliferation of mutant TM cells, the MyocY437H TM cells were cultured alone, with TMSCs in the Transwell inserts, or in direct contact with TMSCs. When cells reached 70% confluence, EdU was added into the culture medium to reach 10 µM concentration and incubated for 2 hr. The cells were then trypsinized, fixed with 4% paraformaldehyde, permeabilized with 0.5% of Triton X-100 and blocked with 1% bovine serum albumin (BSA). Subsequently, a cocktail containing sodium ascorbate (10 mM), azide-fluor 545 (8 µM), and copper sulfate (1 mM) was added and incubated for 10 min. Cells not undergoing the staining procedure, and cells incubating with azide-fluor 545 only were used as controls. Cell samples were run on the flow cytometer to gate both GFP+ mutant TM cells and EdU+ cells. The analysis was done using FlowJo_V10 software (FlowJo, Ashland, OR) and the percentage of EdU+ cells was counted as the number of GFP+EdU+ cells divided by GFP+ cells x 100. Each group was replicated at least three times.</p></sec><sec id="s4-12"><title>Western blotting analysis</title><p>Cultured cells, aqueous humor and mouse limbus tissue were lysed with RIPA buffer (Santa Cruz Biotechnology). BCA Protein Assay Kit (Pierce Biotechnology) was utilized for evaluating the concentration of proteins. A total of 30 μg total protein was loaded in each well and electrophoresed on the sodium dodecyl sulfate–polyacrylamide gel (ThermoFisher) and transferred to the PVDF membrane. After blocking in the blocking buffer, the membrane was incubated overnight with following primary antibodies accordingly, anti-CHI3L1, anti-Myoc, anti-elastin (Sigma), anti-Grp78, anti-fibronectin, and anti-collagen IV (Abcam). After washing with 0.1% Tween 20 in Tris-buffered saline for three times, it was incubated with secondary antibodies (IRDye 680LT and IRDye 800CW, LI-COR Biosciences). Fluorescent signals were captured on an infrared imager (Odyssey; LI-COR Biosciences). ImageJ was used for the densitometry analysis of protein expression. Each experiment was repeated three times.</p></sec><sec id="s4-13"><title>Anterior segment optical coherence tomography (OCT)</title><p>For evaluation of central corneal thickness and peripheral anterior synechia, an anterior segment optical coherence tomography (OCT; Visante OCT MODEL 1000; Carl Zeiss Meditec, Dublin, CA) was used. Eight eyes of each group were examined by determining quadrant-scans along four axes (0°–180°, 45°–225°, 90°–270°, and 135°–315°) to ensure scanning through the central cornea and data along the 0° to 180° axis were used for analysis.</p></sec><sec id="s4-14"><title>Pattern electroretinography (PERG)</title><p>PERG was performed on the Celeris apparatus (Diagnosys LLC, Lowell, MA) to evaluate the RGC function. Mice (n = 10 eyes for each group) were anesthetized with intraperitoneal injections of the mixture of ketamine and xylazine. The murine pupil was dilated with 0.5% tropicamide and 2.5% phenylephrine eye drops. A circular electrode centered on the cornea was placed in a plane perpendicular to the visual axis. Pattern stimuli consisted of horizontal bars of variable spatial frequencies and contrast that alternate at different temporal frequency. The parameters for PERG amplitude were spatial frequency 0.155 cycles/degree, temporal frequency 2.1 reversals/sec, contrast 100% and substantial averaging (600–1800 sweeps). The data were analyzed by the software Espion V6 (Diagnosys). The amplitude of P1 was used to analyze the function of RGCs.</p></sec><sec id="s4-15"><title>RNA sequencing</title><p>Three strains of cultured TMSCs and corneal fibroblasts isolated and cultured as previously described (<xref ref-type="bibr" rid="bib12">Du et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Yun et al., 2018</xref>) from different donors were lysed in RLT buffer (Qiagen). RNA isolation was performed using RNeasy mini kit (Qiagen) as per manufacturer’s instructions. RNA pellet was treated with Ambion RNase-free DNase in DNase one buffer (Invitrogen). Final RNA pellet was dissolved in RNase-free diethyl pyrocarbonate (DEPC) water and sent to GENEWIZ, LLC. (South Plainfield, NJ, USA) for RNA sequencing. The interactive heatmap was generated using Clustergrammer (<xref ref-type="bibr" rid="bib15">Fernandez et al., 2017</xref>) which is freely available at <ext-link ext-link-type="uri" xlink:href="http://amp.pharm.mssm.edu/clustergrammer/">http://amp.pharm.mssm.edu/clustergrammer/</ext-link>. Prior to displaying the heatmap, the raw gene counts were normalized using the logCPM method, filtered by selecting the genes with most variable expression, and finally transformed using the Z-score method with false discover rate (FDR) &lt; 1%. Interactome networks were generated using STRING v11 (<xref ref-type="bibr" rid="bib43">Szklarczyk et al., 2019</xref>).</p></sec><sec id="s4-16"><title>Statistical analysis</title><p>The results were expressed as mean ± standard deviation (SD). The statistical differences were analyzed by one-way or two-way ANOVA followed by Tukey’s multiple comparisons test using GraphPad Prism 8. p&lt;0.05 was considered statistically significance.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The work was supported by NIH grants EY025643 (YD), P30-EY008098, Research to Prevent Blindness; and Eye and Ear Foundation (Pittsburgh, PA). The authors thank Kira Lathrop for assisting with confocal microscopy, Nancy Zurowski with Flow Cytometry, Katherine Davoli for paraffin sectioning, and Ming Sun for TEM sectioning.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>The University of Pittsburgh has a patent named &quot;trabecular meshwork stem cells&quot; with Yiqin Du as one of the inventors.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Data curation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: All the experiments conducted on the animals were approved by the University of Pittsburgh Institutional Animal Care (protocol 18022317) and Use Committee and complied with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Human cell culture was approved by the Committee for Oversight of Research and Clinical Training Involving Decedents (CORID No. 161).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Related gene expression increase (p&lt;0.05) in genes related to TM ECM interaction.</title><p>Related to <xref ref-type="fig" rid="fig9">Figure 9</xref>.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-63677-supp1-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-63677-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1–9.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Hassan</surname> <given-names>DW</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Ryan</surname> <given-names>EI</given-names></name><name><surname>Acott</surname> <given-names>TS</given-names></name><name><surname>Kelley</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Induced pluripotent stem cells restore function in a human cell loss model of open-angle Glaucoma</article-title><source>Stem Cells</source><volume>33</volume><fpage>751</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1002/stem.1885</pub-id><pub-id pub-id-type="pmid">25377070</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acott</surname> <given-names>TS</given-names></name><name><surname>Kelley</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Extracellular matrix in the trabecular meshwork</article-title><source>Experimental Eye Research</source><volume>86</volume><fpage>543</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2008.01.013</pub-id><pub-id pub-id-type="pmid">18313051</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarado</surname> <given-names>J</given-names></name><name><surname>Murphy</surname> <given-names>C</given-names></name><name><surname>Polansky</surname> <given-names>J</given-names></name><name><surname>Juster</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Age-related changes in trabecular meshwork cellularity</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>21</volume><fpage>714</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">7298275</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarado</surname> <given-names>J</given-names></name><name><surname>Murphy</surname> <given-names>C</given-names></name><name><surname>Juster</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Trabecular meshwork cellularity in primary open-angle Glaucoma and nonglaucomatous normals</article-title><source>Ophthalmology</source><volume>91</volume><fpage>564</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(84)34248-8</pub-id><pub-id pub-id-type="pmid">6462622</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname> <given-names>S</given-names></name><name><surname>Hertsenberg</surname> <given-names>AJ</given-names></name><name><surname>Funderburgh</surname> <given-names>ML</given-names></name><name><surname>Burrow</surname> <given-names>MK</given-names></name><name><surname>Mann</surname> <given-names>MM</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Lathrop</surname> <given-names>KL</given-names></name><name><surname>Syed-Picard</surname> <given-names>FN</given-names></name><name><surname>Adams</surname> <given-names>SM</given-names></name><name><surname>Birk</surname> <given-names>DE</given-names></name><name><surname>Funderburgh</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Human limbal biopsy-derived stromal stem cells prevent corneal scarring</article-title><source>Science Translational Medicine</source><volume>6</volume><elocation-id>266ra172</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3009644</pub-id><pub-id pub-id-type="pmid">25504883</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braunger</surname> <given-names>BM</given-names></name><name><surname>Ademoglu</surname> <given-names>B</given-names></name><name><surname>Koschade</surname> <given-names>SE</given-names></name><name><surname>Fuchshofer</surname> <given-names>R</given-names></name><name><surname>B'Ann</surname> <given-names>TG</given-names></name><name><surname>Kiland</surname> <given-names>JA</given-names></name><name><surname>Hennes-Beann</surname> <given-names>EA</given-names></name><name><surname>Brunner</surname> <given-names>KG</given-names></name><name><surname>Kaufman</surname> <given-names>PL</given-names></name><name><surname>Tamm</surname> <given-names>ER</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of adult stem cells in Schwalbe's Line Region of the Primate Eye</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>55</volume><fpage>7499</fpage><lpage>7507</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-14872</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broman</surname> <given-names>AT</given-names></name><name><surname>Quigley</surname> <given-names>HA</given-names></name><name><surname>West</surname> <given-names>SK</given-names></name><name><surname>Katz</surname> <given-names>J</given-names></name><name><surname>Munoz</surname> <given-names>B</given-names></name><name><surname>Bandeen-Roche</surname> <given-names>K</given-names></name><name><surname>Tielsch</surname> <given-names>JM</given-names></name><name><surname>Friedman</surname> <given-names>DS</given-names></name><name><surname>Crowston</surname> <given-names>J</given-names></name><name><surname>Taylor</surname> <given-names>HR</given-names></name><name><surname>Varma</surname> <given-names>R</given-names></name><name><surname>Leske</surname> <given-names>MC</given-names></name><name><surname>Bengtsson</surname> <given-names>B</given-names></name><name><surname>Heijl</surname> <given-names>A</given-names></name><name><surname>He</surname> <given-names>M</given-names></name><name><surname>Foster</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Estimating the rate of progressive visual field damage in those with Open-Angle Glaucoma, from Cross-Sectional data</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>49</volume><fpage>66</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1167/iovs.07-0866</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buller</surname> <given-names>C</given-names></name><name><surname>Johnson</surname> <given-names>DH</given-names></name><name><surname>Tschumper</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Human trabecular meshwork phagocytosis observations in an organ culture system</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>31</volume><fpage>2156</fpage><lpage>2163</lpage><pub-id pub-id-type="pmid">2211012</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campeau</surname> <given-names>E</given-names></name><name><surname>Ruhl</surname> <given-names>VE</given-names></name><name><surname>Rodier</surname> <given-names>F</given-names></name><name><surname>Smith</surname> <given-names>CL</given-names></name><name><surname>Rahmberg</surname> <given-names>BL</given-names></name><name><surname>Fuss</surname> <given-names>JO</given-names></name><name><surname>Campisi</surname> <given-names>J</given-names></name><name><surname>Yaswen</surname> <given-names>P</given-names></name><name><surname>Cooper</surname> <given-names>PK</given-names></name><name><surname>Kaufman</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A versatile viral system for expression and depletion of proteins in mammalian cells</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e6529</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006529</pub-id><pub-id pub-id-type="pmid">19657394</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname> <given-names>A</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Trabecular meshwork regeneration - A potential treatment for Glaucoma</article-title><source>Current Ophthalmology Reports</source><volume>7</volume><fpage>80</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1007/s40135-019-00203-2</pub-id><pub-id pub-id-type="pmid">31316866</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname> <given-names>AC</given-names></name><name><surname>Stasko</surname> <given-names>MR</given-names></name><name><surname>Stoffel</surname> <given-names>M</given-names></name><name><surname>Scott-McKean</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>G-protein-gated potassium (GIRK) channels containing the GIRK2 subunit are control hubs for pharmacologically induced hypothermic responses</article-title><source>Journal of Neuroscience</source><volume>25</volume><fpage>7801</fpage><lpage>7804</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1699-05.2005</pub-id><pub-id pub-id-type="pmid">16120781</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Carlson</surname> <given-names>EC</given-names></name><name><surname>Funderburgh</surname> <given-names>ML</given-names></name><name><surname>Birk</surname> <given-names>DE</given-names></name><name><surname>Pearlman</surname> <given-names>E</given-names></name><name><surname>Guo</surname> <given-names>N</given-names></name><name><surname>Kao</surname> <given-names>WW</given-names></name><name><surname>Funderburgh</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Stem cell therapy restores transparency to defective murine corneas</article-title><source>Stem Cells</source><volume>27</volume><fpage>1635</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1002/stem.91</pub-id><pub-id pub-id-type="pmid">19544455</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Roh</surname> <given-names>DS</given-names></name><name><surname>Mann</surname> <given-names>MM</given-names></name><name><surname>Funderburgh</surname> <given-names>ML</given-names></name><name><surname>Funderburgh</surname> <given-names>JL</given-names></name><name><surname>Schuman</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Multipotent stem cells from trabecular meshwork become phagocytic TM cells</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>53</volume><fpage>1566</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1167/iovs.11-9134</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Yun</surname> <given-names>H</given-names></name><name><surname>Yang</surname> <given-names>E</given-names></name><name><surname>Schuman</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Stem cells from trabecular meshwork home to TM tissue in vivo</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>54</volume><fpage>1450</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-11056</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname> <given-names>NF</given-names></name><name><surname>Gundersen</surname> <given-names>GW</given-names></name><name><surname>Rahman</surname> <given-names>A</given-names></name><name><surname>Grimes</surname> <given-names>ML</given-names></name><name><surname>Rikova</surname> <given-names>K</given-names></name><name><surname>Hornbeck</surname> <given-names>P</given-names></name><name><surname>Ma'ayan</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clustergrammer, a web-based heatmap visualization and analysis tool for high-dimensional biological data</article-title><source>Scientific Data</source><volume>4</volume><elocation-id>170151</elocation-id><pub-id pub-id-type="doi">10.1038/sdata.2017.151</pub-id><pub-id pub-id-type="pmid">28994825</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fingert</surname> <given-names>JH</given-names></name><name><surname>Stone</surname> <given-names>EM</given-names></name><name><surname>Sheffield</surname> <given-names>VC</given-names></name><name><surname>Alward</surname> <given-names>WL</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Myocilin glaucoma</article-title><source>Survey of Ophthalmology</source><volume>47</volume><fpage>547</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1016/S0039-6257(02)00353-3</pub-id><pub-id pub-id-type="pmid">12504739</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagen</surname> <given-names>D</given-names></name><name><surname>Faralli</surname> <given-names>JA</given-names></name><name><surname>Filla</surname> <given-names>MS</given-names></name><name><surname>Peters</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The role of integrins in the trabecular meshwork</article-title><source>Journal of Ocular Pharmacology and Therapeutics</source><volume>30</volume><fpage>110</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1089/jop.2013.0176</pub-id><pub-id pub-id-type="pmid">24266581</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gong</surname> <given-names>HSD</given-names></name></person-group><year iso-8601-date="2016">2016</year><chapter-title>The histopathological changes in the trabecular outflow pathway and their possible effects on aqueous outflow in eyes with primary open-angle glaucoma</chapter-title><person-group person-group-type="editor"><name><surname>Samples</surname> <given-names>J. R</given-names></name><name><surname>Knepper</surname> <given-names>P. A</given-names></name></person-group><source>Glaucoma Research and Clinical Advances</source><publisher-name>Kugler Amsterdam</publisher-name><fpage>17</fpage><lpage>40</lpage></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heijl</surname> <given-names>A</given-names></name><name><surname>Leske</surname> <given-names>MC</given-names></name><name><surname>Bengtsson</surname> <given-names>B</given-names></name><name><surname>Hyman</surname> <given-names>L</given-names></name><name><surname>Bengtsson</surname> <given-names>B</given-names></name><name><surname>Hussein</surname> <given-names>M</given-names></name><collab>Early Manifest Glaucoma Trial Group</collab></person-group><year iso-8601-date="2002">2002</year><article-title>Reduction of intraocular pressure and Glaucoma progression: results from the early manifest Glaucoma trial</article-title><source>Archives of Ophthalmology</source><volume>120</volume><fpage>1268</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1001/archopht.120.10.1268</pub-id><pub-id pub-id-type="pmid">12365904</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname> <given-names>SF</given-names></name><name><surname>Gorgels</surname> <given-names>TGMF</given-names></name><name><surname>Ramdas</surname> <given-names>WD</given-names></name><name><surname>Klaver</surname> <given-names>CCW</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>Jansonius</surname> <given-names>NM</given-names></name><name><surname>Bergen</surname> <given-names>AAB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The vast complexity of primary open angle Glaucoma: disease genes, risks, molecular mechanisms and pathobiology</article-title><source>Progress in Retinal and Eye Research</source><volume>37</volume><fpage>31</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2013.09.001</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasetti</surname> <given-names>RB</given-names></name><name><surname>Phan</surname> <given-names>TN</given-names></name><name><surname>Millar</surname> <given-names>JC</given-names></name><name><surname>Zode</surname> <given-names>GS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Expression of mutant myocilin induces abnormal intracellular accumulation of selected extracellular matrix proteins in the trabecular meshwork</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>57</volume><fpage>6058</fpage><lpage>6069</lpage><pub-id pub-id-type="doi">10.1167/iovs.16-19610</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasetti</surname> <given-names>RB</given-names></name><name><surname>Maddineni</surname> <given-names>P</given-names></name><name><surname>Millar</surname> <given-names>JC</given-names></name><name><surname>Clark</surname> <given-names>AF</given-names></name><name><surname>Zode</surname> <given-names>GS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Increased synthesis and deposition of extracellular matrix proteins leads to endoplasmic reticulum stress in the trabecular meshwork</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>14951</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-14938-0</pub-id><pub-id pub-id-type="pmid">29097767</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname> <given-names>KE</given-names></name><name><surname>Aga</surname> <given-names>M</given-names></name><name><surname>Bradley</surname> <given-names>JM</given-names></name><name><surname>Kelley</surname> <given-names>MJ</given-names></name><name><surname>Acott</surname> <given-names>TS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Extracellular matrix turnover and outflow resistance</article-title><source>Experimental Eye Research</source><volume>88</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2008.11.023</pub-id><pub-id pub-id-type="pmid">19087875</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname> <given-names>KE</given-names></name><name><surname>Bhattacharya</surname> <given-names>SK</given-names></name><name><surname>Borrás</surname> <given-names>T</given-names></name><name><surname>Brunner</surname> <given-names>TM</given-names></name><name><surname>Chansangpetch</surname> <given-names>S</given-names></name><name><surname>Clark</surname> <given-names>AF</given-names></name><name><surname>Dismuke</surname> <given-names>WM</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Elliott</surname> <given-names>MH</given-names></name><name><surname>Ethier</surname> <given-names>CR</given-names></name><name><surname>Faralli</surname> <given-names>JA</given-names></name><name><surname>Freddo</surname> <given-names>TF</given-names></name><name><surname>Fuchshofer</surname> <given-names>R</given-names></name><name><surname>Giovingo</surname> <given-names>M</given-names></name><name><surname>Gong</surname> <given-names>H</given-names></name><name><surname>Gonzalez</surname> <given-names>P</given-names></name><name><surname>Huang</surname> <given-names>A</given-names></name><name><surname>Johnstone</surname> <given-names>MA</given-names></name><name><surname>Kaufman</surname> <given-names>PL</given-names></name><name><surname>Kelley</surname> <given-names>MJ</given-names></name><name><surname>Knepper</surname> <given-names>PA</given-names></name><name><surname>Kopczynski</surname> <given-names>CC</given-names></name><name><surname>Kuchtey</surname> <given-names>JG</given-names></name><name><surname>Kuchtey</surname> <given-names>RW</given-names></name><name><surname>Kuehn</surname> <given-names>MH</given-names></name><name><surname>Lieberman</surname> <given-names>RL</given-names></name><name><surname>Lin</surname> <given-names>SC</given-names></name><name><surname>Liton</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Lütjen-Drecoll</surname> <given-names>E</given-names></name><name><surname>Mao</surname> <given-names>W</given-names></name><name><surname>Masis-Solano</surname> <given-names>M</given-names></name><name><surname>McDonnell</surname> <given-names>F</given-names></name><name><surname>McDowell</surname> <given-names>CM</given-names></name><name><surname>Overby</surname> <given-names>DR</given-names></name><name><surname>Pattabiraman</surname> <given-names>PP</given-names></name><name><surname>Raghunathan</surname> <given-names>VK</given-names></name><name><surname>Rao</surname> <given-names>PV</given-names></name><name><surname>Rhee</surname> <given-names>DJ</given-names></name><name><surname>Chowdhury</surname> <given-names>UR</given-names></name><name><surname>Russell</surname> <given-names>P</given-names></name><name><surname>Samples</surname> <given-names>JR</given-names></name><name><surname>Schwartz</surname> <given-names>D</given-names></name><name><surname>Stubbs</surname> <given-names>EB</given-names></name><name><surname>Tamm</surname> <given-names>ER</given-names></name><name><surname>Tan</surname> <given-names>JC</given-names></name><name><surname>Toris</surname> <given-names>CB</given-names></name><name><surname>Torrejon</surname> <given-names>KY</given-names></name><name><surname>Vranka</surname> <given-names>JA</given-names></name><name><surname>Wirtz</surname> <given-names>MK</given-names></name><name><surname>Yorio</surname> <given-names>T</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Zode</surname> <given-names>GS</given-names></name><name><surname>Fautsch</surname> <given-names>MP</given-names></name><name><surname>Peters</surname> <given-names>DM</given-names></name><name><surname>Acott</surname> <given-names>TS</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Consensus recommendations for trabecular meshwork cell isolation, characterization and culture</article-title><source>Experimental Eye Research</source><volume>171</volume><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2018.03.001</pub-id><pub-id pub-id-type="pmid">29526795</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname> <given-names>MJ</given-names></name><name><surname>Rose</surname> <given-names>AY</given-names></name><name><surname>Keller</surname> <given-names>KE</given-names></name><name><surname>Hessle</surname> <given-names>H</given-names></name><name><surname>Samples</surname> <given-names>JR</given-names></name><name><surname>Acott</surname> <given-names>TS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Stem cells in the trabecular meshwork: present and future promises</article-title><source>Experimental Eye Research</source><volume>88</volume><fpage>747</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2008.10.024</pub-id><pub-id pub-id-type="pmid">19061887</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>E</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fidelity of long-term cryopreserved adipose-derived stem cells for differentiation into cells of ocular and other lineages</article-title><source>Experimental Eye Research</source><volume>189</volume><elocation-id>107860</elocation-id><pub-id pub-id-type="doi">10.1016/j.exer.2019.107860</pub-id><pub-id pub-id-type="pmid">31655040</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Stem cells from human trabecular meshwork hold the potential to develop into ocular and Non-Ocular lineages after Long-Term storage</article-title><source>Stem Cells and Development</source><volume>29</volume><fpage>49</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1089/scd.2019.0169</pub-id><pub-id pub-id-type="pmid">31680626</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname> <given-names>Y</given-names></name><name><surname>Overby</surname> <given-names>DR</given-names></name><name><surname>Boussommier-Calleja</surname> <given-names>A</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name><name><surname>Ethier</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Outflow physiology of the mouse eye: pressure dependence and washout</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>52</volume><fpage>1865</fpage><lpage>1871</lpage><pub-id pub-id-type="doi">10.1167/iovs.10-6019</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liesenborghs</surname> <given-names>I</given-names></name><name><surname>Eijssen</surname> <given-names>LMT</given-names></name><name><surname>Kutmon</surname> <given-names>M</given-names></name><name><surname>Gorgels</surname> <given-names>T</given-names></name><name><surname>Evelo</surname> <given-names>CT</given-names></name><name><surname>Beckers</surname> <given-names>HJM</given-names></name><name><surname>Webers</surname> <given-names>CAB</given-names></name><name><surname>Schouten</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Comprehensive bioinformatics analysis of trabecular meshwork gene expression data to unravel the molecular pathogenesis of primary open-angle Glaucoma</article-title><source>Acta Ophthalmologica</source><volume>98</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1111/aos.14154</pub-id><pub-id pub-id-type="pmid">31197946</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liton</surname> <given-names>PB</given-names></name><name><surname>Luna</surname> <given-names>C</given-names></name><name><surname>Challa</surname> <given-names>P</given-names></name><name><surname>Epstein</surname> <given-names>DL</given-names></name><name><surname>Gonzalez</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Genome-wide expression profile of human trabecular meshwork cultured cells, nonglaucomatous and primary open angle Glaucoma tissue</article-title><source>Molecular Vision</source><volume>12</volume><fpage>774</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">16862071</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manuguerra-Gagné</surname> <given-names>R</given-names></name><name><surname>Boulos</surname> <given-names>PR</given-names></name><name><surname>Ammar</surname> <given-names>A</given-names></name><name><surname>Leblond</surname> <given-names>FA</given-names></name><name><surname>Krosl</surname> <given-names>G</given-names></name><name><surname>Pichette</surname> <given-names>V</given-names></name><name><surname>Lesk</surname> <given-names>MR</given-names></name><name><surname>Roy</surname> <given-names>DC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Transplantation of mesenchymal stem cells promotes tissue regeneration in a Glaucoma model through laser-induced paracrine factor secretion and progenitor cell recruitment</article-title><source>Stem Cells</source><volume>31</volume><fpage>1136</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1002/stem.1364</pub-id><pub-id pub-id-type="pmid">23495088</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname> <given-names>T</given-names></name><name><surname>Cepko</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Electroporation and RNA interference in the rodent retina in vivo and in vitro</article-title><source>PNAS</source><volume>101</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1073/pnas.2235688100</pub-id><pub-id pub-id-type="pmid">14603031</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ophoff</surname> <given-names>RA</given-names></name><name><surname>Terwindt</surname> <given-names>GM</given-names></name><name><surname>Vergouwe</surname> <given-names>MN</given-names></name><name><surname>van Eijk</surname> <given-names>R</given-names></name><name><surname>Oefner</surname> <given-names>PJ</given-names></name><name><surname>Hoffman</surname> <given-names>SM</given-names></name><name><surname>Lamerdin</surname> <given-names>JE</given-names></name><name><surname>Mohrenweiser</surname> <given-names>HW</given-names></name><name><surname>Bulman</surname> <given-names>DE</given-names></name><name><surname>Ferrari</surname> <given-names>M</given-names></name><name><surname>Haan</surname> <given-names>J</given-names></name><name><surname>Lindhout</surname> <given-names>D</given-names></name><name><surname>van Ommen</surname> <given-names>GJ</given-names></name><name><surname>Hofker</surname> <given-names>MH</given-names></name><name><surname>Ferrari</surname> <given-names>MD</given-names></name><name><surname>Frants</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4</article-title><source>Cell</source><volume>87</volume><fpage>543</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81373-2</pub-id><pub-id pub-id-type="pmid">8898206</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname> <given-names>C</given-names></name><name><surname>Martin</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Stem cell approaches to Glaucoma: from aqueous outflow modulation to retinal neuroprotection</article-title><source>Progress in Brain Research</source><volume>220</volume><fpage>241</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/bs.pbr.2015.04.005</pub-id><pub-id pub-id-type="pmid">26497794</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname> <given-names>JC</given-names></name><name><surname>Bhattacharya</surname> <given-names>S</given-names></name><name><surname>Clark</surname> <given-names>AF</given-names></name><name><surname>Zode</surname> <given-names>GS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Increased endoplasmic reticulum stress in human glaucomatous trabecular meshwork cells and tissues</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>56</volume><fpage>3860</fpage><lpage>3868</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-16220</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quigley</surname> <given-names>HA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The number of people with Glaucoma worldwide in 2010 and 2020</article-title><source>British Journal of Ophthalmology</source><volume>90</volume><fpage>262</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1136/bjo.2005.081224</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raviola</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Schwalbe line's cells: a new cell type in the trabecular meshwork of Macaca mulatta</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>22</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">7056624</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolle</surname> <given-names>T</given-names></name><name><surname>Dallorto</surname> <given-names>L</given-names></name><name><surname>Briamonte</surname> <given-names>C</given-names></name><name><surname>Penna</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Retinal nerve fibre layer and macular thickness analysis with fourier domain optical coherence tomography in subjects with a positive family history for primary open angle Glaucoma</article-title><source>British Journal of Ophthalmology</source><volume>98</volume><fpage>1240</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1136/bjophthalmol-2013-304519</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sena</surname> <given-names>DF</given-names></name><name><surname>Lindsley</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neuroprotection for treatment of Glaucoma in adults</article-title><source>Cochrane Database of Systematic Reviews</source><volume>1</volume><elocation-id>CD006539</elocation-id><pub-id pub-id-type="doi">10.1002/14651858.CD006539.pub4</pub-id><pub-id pub-id-type="pmid">28122126</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoji</surname> <given-names>T</given-names></name><name><surname>Zangwill</surname> <given-names>LM</given-names></name><name><surname>Akagi</surname> <given-names>T</given-names></name><name><surname>Saunders</surname> <given-names>LJ</given-names></name><name><surname>Yarmohammadi</surname> <given-names>A</given-names></name><name><surname>Manalastas</surname> <given-names>PIC</given-names></name><name><surname>Penteado</surname> <given-names>RC</given-names></name><name><surname>Weinreb</surname> <given-names>RN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Progressive macula vessel density loss in primary Open-Angle Glaucoma: a longitudinal study</article-title><source>American Journal of Ophthalmology</source><volume>182</volume><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2017.07.011</pub-id><pub-id pub-id-type="pmid">28734815</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname> <given-names>JH</given-names></name><name><surname>Tian</surname> <given-names>Y</given-names></name><name><surname>Funderburgh</surname> <given-names>J</given-names></name><name><surname>Pellegrini</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>Goldberg</surname> <given-names>JL</given-names></name><name><surname>Ali</surname> <given-names>RR</given-names></name><name><surname>Young</surname> <given-names>M</given-names></name><name><surname>Xie</surname> <given-names>Y</given-names></name><name><surname>Temple</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Regenerating eye tissues to preserve and restore vision</article-title><source>Cell Stem Cell</source><volume>22</volume><fpage>834</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.05.013</pub-id><pub-id pub-id-type="pmid">29859174</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundaresan</surname> <given-names>Y</given-names></name><name><surname>Veerappan</surname> <given-names>M</given-names></name><name><surname>Ramasamy</surname> <given-names>KS</given-names></name><name><surname>Chidambaranathan</surname> <given-names>GP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification, quantification and age-related changes of human trabecular meshwork stem cells</article-title><source>Eye and Vision</source><volume>6</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.1186/s40662-019-0156-z</pub-id><pub-id pub-id-type="pmid">31641682</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname> <given-names>D</given-names></name><name><surname>Gable</surname> <given-names>AL</given-names></name><name><surname>Lyon</surname> <given-names>D</given-names></name><name><surname>Junge</surname> <given-names>A</given-names></name><name><surname>Wyder</surname> <given-names>S</given-names></name><name><surname>Huerta-Cepas</surname> <given-names>J</given-names></name><name><surname>Simonovic</surname> <given-names>M</given-names></name><name><surname>Doncheva</surname> <given-names>NT</given-names></name><name><surname>Morris</surname> <given-names>JH</given-names></name><name><surname>Bork</surname> <given-names>P</given-names></name><name><surname>Jensen</surname> <given-names>LJ</given-names></name><name><surname>Mering</surname> <given-names>CV</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D607</fpage><lpage>D613</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id><pub-id pub-id-type="pmid">30476243</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamm</surname> <given-names>ER</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Myocilin and Glaucoma: facts and ideas</article-title><source>Progress in Retinal and Eye Research</source><volume>21</volume><fpage>395</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1016/S1350-9462(02)00010-1</pub-id><pub-id pub-id-type="pmid">12150989</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urban</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The role of the physicochemical environment in determining disc cell behaviour</article-title><source>Biochemical Society Transactions</source><volume>30</volume><fpage>858</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1042/bst0300858</pub-id><pub-id pub-id-type="pmid">12440933</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villegas</surname> <given-names>SN</given-names></name><name><surname>Rothová</surname> <given-names>M</given-names></name><name><surname>Barrios-Llerena</surname> <given-names>ME</given-names></name><name><surname>Pulina</surname> <given-names>M</given-names></name><name><surname>Hadjantonakis</surname> <given-names>AK</given-names></name><name><surname>Le Bihan</surname> <given-names>T</given-names></name><name><surname>Astrof</surname> <given-names>S</given-names></name><name><surname>Brickman</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PI3K/Akt1 signalling specifies foregut precursors by generating regionalized extra-cellular matrix</article-title><source>eLife</source><volume>2</volume><elocation-id>e00806</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.00806</pub-id><pub-id pub-id-type="pmid">24368729</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vranka</surname> <given-names>JA</given-names></name><name><surname>Kelley</surname> <given-names>MJ</given-names></name><name><surname>Acott</surname> <given-names>TS</given-names></name><name><surname>Keller</surname> <given-names>KE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in Glaucoma</article-title><source>Experimental Eye Research</source><volume>133</volume><fpage>112</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2014.07.014</pub-id><pub-id pub-id-type="pmid">25819459</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Osakue</surname> <given-names>D</given-names></name><name><surname>Yang</surname> <given-names>E</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Gong</surname> <given-names>H</given-names></name><name><surname>Xia</surname> <given-names>X</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Endoplasmic reticulum stress response of trabecular meshwork stem cells and trabecular meshwork cells and protective effects of activated PERK pathway</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>60</volume><fpage>265</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1167/iovs.18-25477</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wuertz</surname> <given-names>K</given-names></name><name><surname>Godburn</surname> <given-names>K</given-names></name><name><surname>Neidlinger-Wilke</surname> <given-names>C</given-names></name><name><surname>Urban</surname> <given-names>J</given-names></name><name><surname>Iatridis</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Behavior of mesenchymal stem cells in the chemical microenvironment of the intervertebral disc</article-title><source>Spine</source><volume>33</volume><fpage>1843</fpage><lpage>1849</lpage><pub-id pub-id-type="doi">10.1097/BRS.0b013e31817b8f53</pub-id><pub-id pub-id-type="pmid">18670337</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Peters</surname> <given-names>DM</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>??5β1 integrin promotes anchoring and integration of transplanted stem cells to the trabecular meshwork in the eye for regeneration</article-title><source>Stem Cells and Development</source><volume>29</volume><fpage>290</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1089/scd.2019.0254</pub-id><pub-id pub-id-type="pmid">31854234</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname> <given-names>H</given-names></name><name><surname>Lathrop</surname> <given-names>KL</given-names></name><name><surname>Yang</surname> <given-names>E</given-names></name><name><surname>Sun</surname> <given-names>M</given-names></name><name><surname>Kagemann</surname> <given-names>L</given-names></name><name><surname>Fu</surname> <given-names>V</given-names></name><name><surname>Stolz</surname> <given-names>DB</given-names></name><name><surname>Schuman</surname> <given-names>JS</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A laser-induced mouse model with long-term intraocular pressure elevation</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e107446</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0107446</pub-id><pub-id pub-id-type="pmid">25216052</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname> <given-names>H</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Wills</surname> <given-names>A</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Stem cells in the trabecular meshwork for regulating intraocular pressure</article-title><source>Journal of Ocular Pharmacology and Therapeutics</source><volume>32</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1089/jop.2016.0005</pub-id><pub-id pub-id-type="pmid">27183473</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Sun</surname> <given-names>M</given-names></name><name><surname>Stolz</surname> <given-names>DB</given-names></name><name><surname>Xia</surname> <given-names>X</given-names></name><name><surname>Ethier</surname> <given-names>CR</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human stem cells home to and repair laser-damaged trabecular meshwork in a mouse model</article-title><source>Communications Biology</source><volume>1</volume><elocation-id>216</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-018-0227-z</pub-id><pub-id pub-id-type="pmid">30534608</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zadoo</surname> <given-names>S</given-names></name><name><surname>Nguyen</surname> <given-names>A</given-names></name><name><surname>Zode</surname> <given-names>G</given-names></name><name><surname>Hulleman</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A novel luciferase assay for sensitively monitoring myocilin variants in cell culture</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>57</volume><fpage>1939</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1167/iovs.15-18789</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Grinchuk</surname> <given-names>O</given-names></name><name><surname>Tomarev</surname> <given-names>SI</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop Glaucoma</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>49</volume><fpage>1932</fpage><lpage>1939</lpage><pub-id pub-id-type="doi">10.1167/iovs.07-1339</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Xia</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>E</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Marra</surname> <given-names>KG</given-names></name><name><surname>Ethier</surname> <given-names>CR</given-names></name><name><surname>Schuman</surname> <given-names>JS</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Adipose-derived stem cells integrate into trabecular meshwork with Glaucoma treatment potential</article-title><source>The FASEB Journal</source><volume>34</volume><fpage>7160</fpage><lpage>7177</lpage><pub-id pub-id-type="doi">10.1096/fj.201902326R</pub-id><pub-id pub-id-type="pmid">32259357</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>W</given-names></name><name><surname>Gramlich</surname> <given-names>OW</given-names></name><name><surname>Laboissonniere</surname> <given-names>L</given-names></name><name><surname>Jain</surname> <given-names>A</given-names></name><name><surname>Sheffield</surname> <given-names>VC</given-names></name><name><surname>Trimarchi</surname> <given-names>JM</given-names></name><name><surname>Tucker</surname> <given-names>BA</given-names></name><name><surname>Kuehn</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transplantation of iPSC-derived TM cells rescues Glaucoma phenotypes in vivo</article-title><source>PNAS</source><volume>113</volume><fpage>E3492</fpage><lpage>E3500</lpage><pub-id pub-id-type="doi">10.1073/pnas.1604153113</pub-id><pub-id pub-id-type="pmid">27274060</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zode</surname> <given-names>GS</given-names></name><name><surname>Kuehn</surname> <given-names>MH</given-names></name><name><surname>Nishimura</surname> <given-names>DY</given-names></name><name><surname>Searby</surname> <given-names>CC</given-names></name><name><surname>Mohan</surname> <given-names>K</given-names></name><name><surname>Grozdanic</surname> <given-names>SD</given-names></name><name><surname>Bugge</surname> <given-names>K</given-names></name><name><surname>Anderson</surname> <given-names>MG</given-names></name><name><surname>Clark</surname> <given-names>AF</given-names></name><name><surname>Stone</surname> <given-names>EM</given-names></name><name><surname>Sheffield</surname> <given-names>VC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle Glaucoma</article-title><source>Journal of Clinical Investigation</source><volume>121</volume><fpage>3542</fpage><lpage>3553</lpage><pub-id pub-id-type="doi">10.1172/JCI58183</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zode</surname> <given-names>GS</given-names></name><name><surname>Bugge</surname> <given-names>KE</given-names></name><name><surname>Mohan</surname> <given-names>K</given-names></name><name><surname>Grozdanic</surname> <given-names>SD</given-names></name><name><surname>Peters</surname> <given-names>JC</given-names></name><name><surname>Koehn</surname> <given-names>DR</given-names></name><name><surname>Anderson</surname> <given-names>MG</given-names></name><name><surname>Kardon</surname> <given-names>RH</given-names></name><name><surname>Stone</surname> <given-names>EM</given-names></name><name><surname>Sheffield</surname> <given-names>VC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Topical ocular sodium 4-Phenylbutyrate rescues Glaucoma in a myocilin mouse model of primary Open-Angle Glaucoma</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>53</volume><fpage>1557</fpage><lpage>1565</lpage><pub-id pub-id-type="doi">10.1167/iovs.11-8837</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63677.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Pera</surname><given-names>Martin</given-names></name><role>Reviewing Editor</role><aff><institution>The Jackson Laboratory</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This study demonstrates the feasibility of stem cell therapy for glaucoma in an animal model.</p><p><bold>Decision letter after peer review:</bold></p><p>[Editors’ note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.]</p><p>Thank you for submitting your work entitled &quot;Stem Cell Transplantation Rescued A Primary Open-Angle Glaucoma Mouse Model&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The reviewers have opted to remain anonymous.</p><p>Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in <italic>eLife</italic>.</p><p>Though both reviewers recognize the importance of this area of research, both have significant concerns regarding the quality of the data. In particular, the fate of the grafted cells, and the mechanism whereby the grafted cells achieve a therapeutic effect, has not been adequately addressed. It seems likely that revision to address these points and other key issues would likely entail very considerable experimental work.</p><p><italic>Reviewer #2:</italic></p><p>The authors report studies of human trabecular meshwork stem cells (TMSC) as a treatment for glaucoma in a transgenic mouse model of glaucoma caused by a myocilin mutation (Tyr437His). Tg-MyocY437H mice loose TM cells; developed reduced outflow facility and high IOP; and reduced PERG. The authors report that intracameral injection of TMSCs in these mice restores outflow facility, lowers IOP, and restores PERG. They also report that the TMSCs help to normalize secretion of Myoc. Normalization of extracellular matrix protein is also reported.</p><p>The authors report using stem cell therapy in a mouse model of glaucoma as a potential therapy for this disease, which is intriguing. Glaucoma is the most common cause of irreversible blindness and better therapies to protect vision are needed and this direction holds promise and would be of interest to the readership</p><p>My most important comments.</p><p>1) Stem cell-based therapeutic studies were previously reported in the same mouse model of glaucoma (Tg-Myoc-Tyr437His) by Zhu et al., 2016. The authors should compare and contrast their findings. The Zhu study reported increased numbers of endogenous TM cells, which raises the question of whether the TMSC delivered in the current study are directly responsible for a therapeutic effect or whether they similarly induce more endogenous TM cells. Are the increased cells seen in the TM in the current study from the TMSC or proliferation of endogenous TM cells? Are they even TM cells?</p><p>2) The authors should more clearly describe and characterize the cells that they are using (TMSC and primary TM cells) to authenticate their identity (i.e. pluripotency assays and markers for TM cells like steroid induction of MYOC)</p><p>3) The authors report PERG as a surrogate for functional damage of glaucoma in the Tg-Myoc-Tyr437His mice, but RGC counts and/or optic nerve axon counts is a more standard assessment for glaucoma in mice.</p><p>4) The analysis of the RNAseq data is inadequate. Significance should be discussed in the context of multiple measures or false discovery rate.</p><p><italic>Reviewer #3:</italic></p><p>In this paper, the authors use stem cell transplantation to rescue POAG. The premise is an exciting one for therapy. However, several shortcomings need to addressed before publication. Concerns and comments are listed below.</p><p>1) Please clarify mouse strains. Mouse strain C57BL/6J or N (not C57BL/6) makes a difference. What is the strain background of Tg-MyocY437H mice? Must compare within the same strain, preferably littermate given the variation of IOP, outflow, and PERG within the strain and between strains. Please report the exact p-values.</p><p>2) Day time IOP numbers between WT, Tg, and Tg-TMSC are modest at best. Tg IOP is elevated at night, according to the original paper describing the transgenic mouse. The authors should check the effect of TMSC implantation on IOP at night to claim reduction for the sake of completeness.</p><p>3) The authors should localize TMSC in the angle and demonstrate engraftment of the TM. If TMSCs are present in some other location, this should be shown as well. How can a reader know that the TMSC is even alive in the angle? Also, control should include injecting another unrelated stem cell type different from TMSC to show specificity.</p><p>4) In Figure 1D, why is the AC depth looking so different?</p><p>5) The outflow numbers are very high. The outflow number for C57Bl/6J mouse is around 3-5 nl/min/mmHg. Did the eyes dry out? Drying increases outflow during measurements.</p><p>6) For PERG, any reason why authors changed parameters from previously published numbers? Please report if there were any changes in latency.</p><p>7) In Figures 3 and 4, the sections are inferior quality. Space labeled SC is actually where the tissue has separated. The collagen IV staining does not look correct. ColIV is expected to mark the basement membrane. Why is it looking punctate? For looking at cellularity and tissue, the authors need to do a plastic section of eyes and grade the TM as in Libby (2003) 299-p1578. Hence the accuracy of the cell count is questionable. Are the position of the sections matched between the controls and the experimental eyes?</p><p>8) In Figure 4, the Myoc staining looks very different from the original 2011 Zode paper. WT Myco stain is barely visible. Please explain the discrepancy. Regarding the blot, there is a doublet in Myco blot. Which band was quantified? The same goes for panels D and F. Please show full gels for all blots, at least in supplement.</p><p>9) Please show higher magnification for ER in EM. For rigor, please quantify and report lumen size and percent of ER where lumen size changed. Again, the CHOP and GRP78 levels in the Tg animals are nowhere near as high as the Zode paper. Please explain.</p><p>10) A cartoon of co-culture technique will enhance understanding. Can the TMSC differentiate TM cells form CLANS? On this point, do the in vivo injected TMSC differentiate into TM cells? Do mouse TM cells induce human TMSC to differentiate into TM cells in vivo? (See point 3)</p><p>11) Please change &quot;three strains of TMSC&quot;. All human TMSC. Please explain why you are sequencing fibroblasts and their origin. Please explain the inconsistency of the increase of specific genes between TM1, 2, and 3. A blanket statement that ECM genes are upregulated based on the data shown in Figure 8 is unwarranted.</p><p>12) The authors have not demonstrated the claim made in conclusion i.e., TMSC differentiates into TM cells in the mouse angle after injecting the stem cells, which is the premise on which the entire paper is geared.</p><p>[Editors’ note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for submitting your article &quot;Stem Cell Transplantation Rescued A Primary Open-Angle Glaucoma Mouse Model&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by one peer reviewer, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>Summary:</p><p>The study reports a preclinical model of cellular therapy for an important eye disorder, and reports possible mechanisms for the therapeutic effects observed</p><p>Revisions:</p><p>1) Figure 2: SC in the frozen sections is better but still does not match the quality of the image that is standard in the field. Specifically WT and Tg Sham. The other two are just passable.</p><p>2) Figure 5: same issue as in 1.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63677.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>[Editors’ note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors’ response to the first round of review.]</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>The authors report studies of human trabecular meshwork stem cells (TMSC) as a treatment for glaucoma in a transgenic mouse model of glaucoma caused by a myocilin mutation (Tyr437His). Tg-MyocY437H mice loose TM cells; developed reduced outflow facility and high IOP; and reduced PERG. The authors report that intracameral injection of TMSCs in these mice restores outflow facility, lowers IOP, and restores PERG. They also report that the TMSCs help to normalize secretion of Myoc. Normalization of extracellular matrix protein is also reported.</p><p>The authors report using stem cell therapy in a mouse model of glaucoma as a potential therapy for this disease, which is intriguing. Glaucoma is the most common cause of irreversible blindness and better therapies to protect vision are needed and this direction holds promise and would be of interest to the readership</p><p>My most important comments.</p><p>1) Stem cell-based therapeutic studies were previously reported in the same mouse model of glaucoma (Tg-Myoc-Tyr437His) by Zhu et al., 2016. The authors should compare and contrast their findings. The Zhu study reported increased numbers of endogenous TM cells, which raises the question of whether the TMSC delivered in the current study are directly responsible for a therapeutic effect or whether they similarly induce more endogenous TM cells. Are the increased cells seen in the TM in the current study from the TMSC or proliferation of endogenous TM cells? Are they even TM cells?</p></disp-quote><p>Thanks for pointing this out. The Zhu study reported the injection of iPSC derived TM-like cells while we reported the injection of human TMSC. The cells are different. In our study, we showed that neither direct contact nor co-culture without contact of TMSC with TM cells could promote TM cells proliferation in vitro (Figure 7). In the co-culturing system, TMSC can differentiate to the cells expressing TM cell markers and responding to dexamethasone with increased myocilin expression; while TMSC cultured alone without TM cells didn't show any changes (Figure 8). In our new added Figure 4, it shows that many DiO-labeled TMSCs were integrated into the TM tissue, similar to our previous finding (Du, 2013, Yun 2018, Xiong 2020). Some of these DiO-labeled TMSCs expressed TM markers AQP1 and CHI3L1 (new added Figure 4). Our data indicate that after transplantation, the increased TM cellularity is mainly due to differentiated TM cells from TMSC, which remodeled extracellular matrix , rescued outflow facility and protected retinal ganglion cells through decreasing IOP. We have added the results in the revised manuscript and added a discussion as below:</p><p>“A previous report(Zhu et al., 2016) indicated that transplantation of TM cells derived for iPSCs stimulated the endogenous TM cell to proliferate to increase the TM cellularity and reduce IOP. Although the cells and underlying mechanisms for the treatment in their study are different from ours, increased amount of TM cells was found in both studies. It indicates that restoration of TM cellularity and remodeling of the TM ECM are crucial for cell-based therapy for glaucoma.”</p><disp-quote content-type="editor-comment"><p>2) The authors should more clearly describe and characterize the cells that they are using (TMSC and primary TM cells) to authenticate their identity (i.e. pluripotency assays and markers for TM cells like steroid induction of MYOC)</p></disp-quote><p>Thanks for pointing this out. We do characterization on all the TMSCs and TM cells we use. We added the following in the manuscript:</p><p>“Human TMSCs were isolated as previously described (Yun et al., 2018) and characterized by flow cytometry to confirm the positive expression of stem cell markers CD73, CD90, CD105, CD166, and negative expression of CD34 and CD45 as previously reported(Kumar et al., 2020; Yun et al., 2018).”.</p><p>We added a new figure as Figure 7B for the TM characterization and added the related method into the Materials and methods:</p><p>“Cultured TM cells were confirmed via Western blotting by their responsiveness to Dex with increased expression of Myoc (Figure 7B) after 100 nM Dex treatment for 5 days, one of the characteristics of TM cells(Keller et al., 2018).”.</p><disp-quote content-type="editor-comment"><p>3) The authors report PERG as a surrogate for functional damage of glaucoma in the Tg-Myoc-Tyr437His mice, but RGC counts and/or optic nerve axon counts is a more standard assessment for glaucoma in mice.</p></disp-quote><p>Thanks for the suggestion. We counted RGCs in the retina sections and put the data as Figure 2C. We added the description in the Materials and methods and added the results as:</p><p>“Furthermore, we counted the RGC numbers on 5-µm paraffin sections (Figure 2C, Figure 2—figure supplement 1). There were 70.48±2.26 RGC cells/mm in the retina of 6-month old WT mice, and 49.22±1.79 cells/mm in that of 6-month old Tg-MyocY437H mice with RGC loss (p&lt;0.0001). The RGCs were preserved/rescued by TMSC transplantation in Tg-MyocY437H mice with the RGC number increased to 60.60±1.25 cells/mm (p&lt;0.0001 as compared to untreated Tg-MyocY437H mice). This confirms that TMSC transplantation prevented/rescued the RGC loss and preserved the RGC function in the Tg-MyocY437H mice.”</p><disp-quote content-type="editor-comment"><p>4) The analysis of the RNAseq data is inadequate. Significance should be discussed in the context of multiple measures or false discovery rate.</p></disp-quote><p>Thanks for the advice. We reanalyzed the RNAseq data as new Figure 9 and edited the Discussion as:</p><p>“We previously reported that TMSCs can regenerate the damaged TM tissue while corneal fibroblasts did not repair the damaged TM tissue(Yun et al., 2018). […] We speculate that the preservation of RGCs and their function in Tg-MYOCY437H model by TMSCs is mainly due to reduced IOP, but these neuroprotective proteins through paracrine secretion by TMSCs might be also involved in the neuroprotective process. Further study is required to uncover it.”</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>In this paper, the authors use stem cell transplantation to rescue POAG. The premise is an exciting one for therapy. However, several shortcomings need to addressed before publication. Concerns and comments are listed below.</p><p>1) Please clarify mouse strains. Mouse strain C57BL/6J or N (not C57BL/6) makes a difference. What is the strain background of Tg-MyocY437H mice? Must compare within the same strain, preferably littermate given the variation of IOP, outflow, and PERG within the strain and between strains. Please report the exact p-values.</p></disp-quote><p>Both the WT and Tg-MyocY437H mice were C57BL/6J mice. We bred the</p><p>Tg-MyocY437H mice with WT C57BL/6J mice in house so every mouse is the same strain. We have added this description in the Materials and methods:</p><p>“Four-month old wildtype (WT) C57BL/6J mice were purchased from Jackson Laboratory as the normal control, and Tg-MyocY437H mice originated from C57BL/6J mice were kindly gifted by Dr. Gulab Zode (North Texas Eye Research Institute, Texas) and transferred to University of Pittsburgh. All the experiments conducted on the animals were approved by the University of Pittsburgh Institutional Animal Care and Use Committee and complied with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Both WT C57B/6J and Tg-MyocY437H C57B/6J mice were bred in the animal facility at University of Pittsburgh. We have reported the exact p-values in each related figure.”</p><disp-quote content-type="editor-comment"><p>2) Day time IOP numbers between WT, Tg, and Tg-TMSC are modest at best. Tg IOP is elevated at night, according to the original paper describing the transgenic mouse. The authors should check the effect of TMSC implantation on IOP at night to claim reduction for the sake of completeness.</p></disp-quote><p>We measured night IOP before the treatment and 60 days after TMSCs transplantation.</p><p>Data were presented as Figure 1B and the results were added to the text:</p><p>“Meanwhile, we measured mouse night IOP which was more obviously elevated than day-time IOP as reported before (Zode et al., 2011). In consistent with the day-time IOP, there was a significant difference of the baseline night IOP between 4-month old Tg-MyocY437H mice (Figure 1B, 17.73±2.25 mmHg) and age-matched WT mice (13.67±2.77 mmHg, P&lt;0.0001). 2 months after TMSC transplantation, the night IOP of Tg-MyocY437H mice (11.75±2.83 mmHg) reduced to the same level as that of WT mice (11.55±2.52 mmHg, P=0.9925).”</p><disp-quote content-type="editor-comment"><p>3) The authors should localize TMSC in the angle and demonstrate engraftment of the TM. If TMSCs are present in some other location, this should be shown as well. How can a reader know that the TMSC is even alive in the angle? Also, control should include injecting another unrelated stem cell type different from TMSC to show specificity.</p></disp-quote><p>In the revised manuscript, we showed that the injected DiO labeled TMSCs were still detectable and alive in TM region by TUNEL staining (Figure 4C) with expression of TM cell markers AQP1 and CHI3L1 (Figure 4A).</p><p>We have previously reported that intracamerally injected fibroblasts were not specifically homed to the TM region and they had gone apoptosis after transplantation (Du 2013, Yun 2018). We added the following in the Discussion:</p><p>“We previously reported that TMSCs can regenerate the damaged TM tissue while corneal fibroblasts did not repair the damaged TM tissue(Yun et al., 2018). Corneal fibroblasts did not express stem cell markers, such as NESTIN or OCT 4, which TMSCs were positive to and the fibroblasts did not home to and anchoring to the TM region after intracamerally injection (Du et al., 2013; Xiong et al., 2020). All these suggest that TMSCs and corneal fibroblasts are distinctive in biological characteristics and behavior.”</p><p>In Discussion, we have added the following:</p><p>“RNAseq analysis showing upregulation of genes related to TM regeneration including maintenance of TM integrity, motility, and ECM interaction in TMSCs as compared to fibroblasts might explain that TMSCs induce regeneration in the Tg-MyocY437H mice via modulation of ECM, promotion of TM integrity and motility, and increasing the oxidative stress defense mechanism of TM cells. In contrast, fibroblasts having much lower expression of the abovementioned genes were unable to produce any regenerative effect as we showed previously(Yun et al., 2018).”</p><disp-quote content-type="editor-comment"><p>4) In Figure 1D, why is the AC depth looking so different?</p></disp-quote><p>We didn't find the difference of AC depth among the groups in the OCT pictures averaged of all the eyes measured. The OCT analysis was utilized to exclude possibility of IOP elevation due to angle closure arising from TMSC transplantation or due to the central corneal depth changes. We have changed it to a more representative figure.</p><disp-quote content-type="editor-comment"><p>5) The outflow numbers are very high. The outflow number for C57Bl/6J mouse is around 3-5 nl/min/mmHg. Did the eyes dry out? Drying increases outflow during measurements.</p></disp-quote><p>We were very careful to keep the eyes moisture throughout the whole perfusion and outflow facility measurement process. Outflow result in this study is consistent with our previous published studies(Zhou et al., 2020 and Yun et al, 2018)</p><disp-quote content-type="editor-comment"><p>6) For PERG, any reason why authors changed parameters from previously published numbers? Please report if there were any changes in latency.</p></disp-quote><p>We did PERG on the Celeris apparatus from the Diagnosys LLC and all the parameters analyzed were from the software Epsion V6 from the same company. We added this description in Materials and methods. We didn’t find any latency difference between groups.</p><disp-quote content-type="editor-comment"><p>7) In Figures 3 and 4, the sections are inferior quality. Space labeled SC is actually where the tissue has separated. The collagen IV staining does not look correct. ColIV is expected to mark the basement membrane. Why is it looking punctate? For looking at cellularity and tissue, the authors need to do a plastic section of eyes and grade the TM as in Libby (2003) 299-p1578. Hence the accuracy of the cell count is questionable. Are the position of the sections matched between the controls and the experimental eyes?</p></disp-quote><p>We admit that plastic sections are the best for counting TM cell numbers. We sectioned the eyes with the same direction and counted the TM cells in the sections when optic nerve could be seen so the counting was in the similar position. In some of the sections, the SC space widened because of tissue processing. With the Col IV staining and the bright field images, the TM region cannot be messed up with any adjacent structures. Collagen IV stains both the basement membrane and extracellular matrix in the TM as a fibrotic marker (Vranka et al., 2015). We have changed the figures which have better quality. In Zhu et al., 2016 paper cryosection was used for immunostaining analysis including counting TM cells number. According to the published data and our experience, we believe our TM cellularity counting on the paraffin sections was accurate and plastic section is not mandatory for the TM cellularity analysis.</p><disp-quote content-type="editor-comment"><p>8) In Figure 4, the Myoc staining looks very different from the original 2011 Zode paper. WT Myco stain is barely visible. Please explain the discrepancy. Regarding the blot, there is a doublet in Myco blot. Which band was quantified? The same goes for panels D and F. Please show full gels for all blots, at least in supplement.</p></disp-quote><p>In current study, Myoc staining was very weak at the TM region in the WT mice and staining intensity increased in Tg group, which was similar to the 2011 Zode paper. According to the published article(N Jacobson , M Andrews, A R Shepard et al. Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor. Hum Mol Genet. 2001, 15;10:117-25), intracellular Myoc protein manifest as two band 55 and 57 kDa, secreted myocilin is variable seen as two bands of 53 and 55KD or single band of 53-55 kDa. We calculated the band density including both bands. Full gels for western blot were submitted for review.</p><disp-quote content-type="editor-comment"><p>9) Please show higher magnification for ER in EM. For rigor, please quantify and report lumen size and percent of ER where lumen size changed. Again, the CHOP and GRP78 levels in the Tg animals are nowhere near as high as the Zode paper. Please explain.</p></disp-quote><p>Thanks for the suggestion. For the ER size, please refer to the answer to reviewer 2’s question 2.</p><p>In Zode paper, the CHOP and GRP78 levels didn't normalized to internal control. According to gel picture in his paper, the difference of GRP78 protein level between WT and Tg group was not as obvious as CHOP level, which is similar to our result. We speculate the time of explosion while capturing picture or the picture contrast gives rise to different gel looking between ours and Zode’s.</p><disp-quote content-type="editor-comment"><p>10) A cartoon of co-culture technique will enhance understanding. Can the TMSC differentiate TM cells form CLANS? On this point, do the in vivo injected TMSC differentiate into TM cells? Do mouse TM cells induce human TMSC to differentiate into TM cells in vivo? (See point 3)</p></disp-quote><p>We added cartoon to explain the co-culture technique (Figure 7C and Figure 8A). After co-culturing with myocilin mutant TM cells, TMSCs expressed TM cell markers and possessed more potent phagocytic ability, and myocilin was increased in the TMSCs after dexamethasone treatment for. In contrast, TMSCs without co-culturing didn't show aforementioned changes. We didn't examine CLAN formation in TMSC differentiated TM cells. According to the suggestion, we also confirmed that transplanted TMSCs can express AQP1 and CHI3L1 at the TM tissue two month after injection, indicating TMSCs can differentiate into TM cells in Tg mice. We can speculate mouse TM cells can stimulate human TMSC to differentiate into TM cells in vivo according to the results from in vitro study.</p><disp-quote content-type="editor-comment"><p>11) Please change &quot;three strains of TMSC&quot;. All human TMSC. Please explain why you are sequencing fibroblasts and their origin. Please explain the inconsistency of the increase of specific genes between TM1, 2, and 3. A blanket statement that ECM genes are upregulated based on the data shown in Figure 8 is unwarranted.</p></disp-quote><p>We did RNAseq on 3 strains of TMSCs and 3 strains of fibroblasts.</p><p>The fibroblast used in this study was originated from donor human cornea. We changed “fibroblasts” as “corneal fibroblasts” in the manuscript and added the description in the Materials and methods:</p><p>“Three strains of cultured TMSCs and corneal fibroblasts isolated and cultured as previously described (Du et al., 2009; Yun et al., 2018) from different donors were lysed in RLT buffer (Qiagen).”</p><p>We added the description in the text:</p><p>“We previously reported that TMSCs can regenerate the damaged TM tissue while corneal fibroblasts did not repair the damaged TM tissue(Yun et al., 2018). Corneal fibroblasts did not express stem cell markers, such as NESTIN or OCT 4, which TMSCs were positive to and the fibroblasts did not home to and anchoring to the TM region after intracamerally injection (Du et al., 2013; Xiong et al., 2020). All these suggest that TMSCs and corneal fibroblasts are distinctive in biological characteristics and behavior. Thus we compared the transcriptomes between TMSCs and corneal fibroblasts.”</p><p>The RNAseq data were from different TMSCs and fibroblasts from different donors so there are variations among donors. We re-analyzed the RNAseq data and changed the Results and the Discussion.</p><disp-quote content-type="editor-comment"><p>12) The authors have not demonstrated the claim made in conclusion i.e., TMSC differentiates into TM cells in the mouse angle after injecting the stem cells, which is the premise on which the entire paper is geared.</p></disp-quote><p>Thanks for the suggestion. In the revision, we have added a new Figure 4 to show the TMSCs differentiates into TM cells expressing AQP1 and CHI3L1. Please refer to the answer to the reviewer 2’s question 1.</p><p>We have reworded the conclusions in the manuscript to make it clear:</p><p>“Conclusion</p><p>Transplanted TMSCs can integrate into the TM tissue and differentiate into functional TM cells that can repopulate the TM tissue, remodel the TM ECM, and restore the TM homeostasis to resolve the outflow facility, eventually reducing IOP and preserving RGCs and their function in the Tg-MyocY437H mouse model of POAG. Myoc mutation glaucoma as a subtype of POAG contains common pathophysiology of POAG that is reduced TM cellularity, which causes abnormal deposition of the ECM and increases IOP and damages the RGCs. Therefore, these results open an important avenue of a novel stem cell-based strategy to eventually treat human open-angle glaucoma.”</p><p>[Editors’ note: what follows is the authors’ response to the second round of review.]</p><disp-quote content-type="editor-comment"><p>Revisions:</p><p>1) Figure 2: SC in the frozen sections is better but still does not match the quality of the image that is standard in the field. Specifically WT and Tg Sham. The other two are just passable.</p></disp-quote><p>Thanks for pointing this out. Since Figure 2 does not contain any staining results, I believe the reviewer meant the figures in Figure 3. We have replaced the staining figures of WT and Tg Sham in Figure 3 and marked the Schlemm’s canal clearer with arrows.</p><disp-quote content-type="editor-comment"><p>2) Figure 5: same issue as in 1.</p></disp-quote><p>We have replaced the staining figures of WT and Tg Sham in Figure 5 and marked the Schlemm’s canal clearer with arrows.</p></body></sub-article></article>